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ABSTRACT 
Psychosocial distress, characterized by increased perceived stress, anxiety and 
mood disturbance, is a common response of women to a diagnosis of breast cancer 
(Northouse, 1992; Pettingale et al., 1988; Stark and House, 2000; Witek-Janusek et al., 
2007). This psychosocial distress leads to activation of the hypothalamic-pituitary-
adrenocortical (HPA) axis and increased circulating glucocorticoids (GCs) (Chrousos, 
2000; Chrousos and Gold, 1992; Schoneveld and Cidlowski, 2007).  Increased 
psychosocial distress and increased HPA activation can lead to immune dysregulation 
consisting of reduced natural killer (NK) cell activity (NKCA) (Biondi, 2001; Kiecolt-
Glaser et al., 1987; Kiecolt-Glaser et al., 2002; Witek-Janusek et al., 2008; Witek-
Janusek et al., 2007). This is of particular relevance to women with breast cancer as 
altered immune cell function is important for tumor control (Curcio et al., 2003; D'Anello 
et al., 2010; Diefenbach and Raulet, 2002; Hartman et al., 2011; Kishimoto, 2005; 
Knupfer and Preiss, 2007; Street et al., 2001; van den Broek et al., 1996).   The 
psychological distress in response to a diagnosis of breast cancer diagnosis has relevance 
for women with breast cancer, as it may contribute to poor cancer outcome. 
Yet little is known about the molecular mechanism(s) by which psychosocial distress 
results in NK cell dysregulation.  The overall purpose of this project was to evaluate a 
potential mechanism posited to underlie altered NK cell function observed in women 
with breast cancer. Increased psychosocial distress increases GCs like cortisol which can 
xii 
 
impact NK cell function; therefore cortisol levels were measured.  Morning cortisol rise 
inversely correlated with NKCA, such that women with decreased NKCA exhibited an 
elevation in the morning cortisol rise.  Additionally, in vitro treatment of a human NK 
cell line, NK92 cells, treated with a synthetic GC (dexamethasone) resulted in decreased 
NKCA.  Together these results suggest that cortisol altered lytic function of NK cells. As 
GCs have been shown to alter cell function by altering epigenetic patterns, global histone 
modifications were investigated.  In both ex vivo analysis of NK cells derived from 
peripheral blood of women with breast cancer and NK92 cells treated with GCs 
significant reductions in global acetylation of histone 4 lysine 8 (H4-K8-Ac) were 
observed, when compared to the age-matched Control women or untreated NK92 cells, 
respectively.  These reductions in H4-K8-Ac correlated with NK cell lytic function as 
measured by NKCA and intracellular perforin levels in NK cells.  Further others show 
GCs alter epigenetic patterns through recruitment of HDACs, thus this was investigated.  
Findings show decreased global H4-K8-Ac patterns in NK cells were associated with 
increased nuclear localization of HDAC2, suggesting that GCs recruit HDAC2 into the 
nucleus causing decreased global H4-K8-Ac and NKCA.  These data identify decreased 
global H4-K8-Ac and increased nuclear localization of HDAC2 as potential markers of 
decreased NK cell lytic activity in women experiencing psychosocial distress.  This 
mechanistic insight advances the field of psychoneuroimmunology by identifying both an 
epigenetic modification (H4-K8-Ac) and a chromatin remodeling protein (HDAC2) as 
indicators of GC mediated immune dysregulation in NK cells of women experiencing 
psychosocial distress. 
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CHAPTER 1 
 
INTRODUCTION 
 
It is well-established that neuro-chemical pathways link the brain and the immune 
system and provide biological pathways whereby one’s emotions influence immune 
function.  The effect of psychological stress on immune function has been, in part, 
attributed to elevations in glucocorticoids (GCs) produced by activation of the 
hypothalamic-pituitary-adrenocortical (HPA) axis [1-3].  GCs can suppress Natural Killer 
(NK) cell lytic activity [4-6] and alter cytokine balance [7-12].   
Previous work has shown that the diagnosis of breast cancer can result in 
increased psychological stress, HPA activation and altered NK cell function [5, 13-17].  
For early stage breast cancer patients, a tumor is removed and prognosis is good, but the 
disease can recur after apparent successful eradication of the tumor.  Recurrence occurs 
in some women but not in others [18].  The reasons are unclear and certainly are multiple, 
but alterations in NK cell function could be a contributing factor.   
However, the molecular mechanism linking psychological stress and GCs to 
reductions in NK cell function remain poorly understood.  It is known, however, that GCs 
affect target cells through alteration of gene transcription and this may result from 
epigenetic modification of histone residues [19]. One unexplored and promising 
possibility is that GCs recruit chromatin remodeling proteins leading to global epigenetic 
modifications resulting in NK cell dysregulation.  Understanding the alterations in 
epigenetic modifications and chromatin remodeling proteins associated with these 
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modifications will allow for a mechanistic understanding of the effects of stress upon the 
immune system and is the focus of this dissertation work. 
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CHAPTER 2 
BACKGROUND 
Breast Cancer and Psychological Consequences: 
 Cancer affects a large number of Americans each year, with an estimate of 
over 1.5 million Americans diagnosed with cancer in 2011 [20].  Of these cancer 
cases, over 230,000 were breast cancer, making breast cancer the most frequently 
diagnosed malignancy in the Western world [20, 21].  In American women, it is the 
second leading cause of cancer death, with over 40,000 American women dying of 
breast cancer yearly [20]. There is clear evidence that a diagnosis of breast cancer can 
have short- as well as long-term psychological consequences [22], characterized by 
increased perceived stress, depressive mood and anxiety [5, 13-17].  Increased mood 
disturbance and increased fatigue also accompany a psychological stressor, such as the 
diagnosis of breast cancer [15, 23-25].  These psychological consequences, termed 
psychosocial distress, are independent of disease state, as women with early stage 
breast cancer, as well as women with metastatic disease both report increased 
psychosocial distress [15, 26, 27].  Additionally, previous work from this laboratory 
found that women who underwent breast biopsy had increased perceived stress 
regardless of biopsy outcome [15].  These results demonstrated that breast cancer 
diagnosis resulted in a psychological and emotional response, termed psychosocial 
distress in this dissertation work.   
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The dynamics of psychosocial distress are influenced by the durationof the 
stressor (i.e. either acute or chronic).  Acute stressors last for minutes to hours, 
whereas chronic stressors lasts months to years [28, 29].  Acute stressors can 
redistribute immune cell trafficking and even increased NK cell function [30-32], 
whereas prolonged chronic stress can dysregulate immune function and undermine 
health [33-36].  Further, depending upon the condition of the stressor or the nature of 
the neuroendocrine response to the stressor, the immune system can be reduced or 
alternatively activated in its function [37, 38].  The impact of psychosocial distress on 
immune function is further discussed below (See Psychosocial Distress and Immune 
function).  Additionally, there are variations in both the intensity and duration of 
psychosocial distress reported in individuals with breast cancer [39].  For some 
individuals the diagnosis of breast cancer activates appropriate allostatic responses.  
Allostasis is defined as “the active process of responding to a challenge to the body by 
triggering chemical mediators of adaptation” [40].  Thus, in some women the 
diagnosis of breast cancer causes an initial, appropriate emotional and biological 
response, which subsides allowing the body to both adapt to the stressor and to return 
to allostasis.  However for others the psychosocial distress is too great resulting in 
increased allostatic load.  Allostatic load is the “wear and tear on the body and brain 
that results from chronic dysregulation (over activity or inactivity) of mediators of 
allostasis” [40].  Approximately 80% of women with breast cancer report some 
psychosocial distress experienced during the initial treatment phases [41].  
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Additionally, an association between increased allostatic load due to early life 
adversity and breast cancer occurrence has been indentified [42].  Individual variation 
makes understanding the psychosocial distress that accompanies breast cancer 
diagnosis even more complex.  For some individuals psychosocial distress subsides 
after the initial cancer diagnosis, for others it continues beyond treatment and recovery 
from the disease [43, 44].   
 
Glucocorticoids: Mediators of Psychosocial Distress: 
Psychosocial distress leads to activation of the hypothalamic-pituitary-
adrenocortical (HPA) axis and the secretion of glucocorticoids (GCs) [1, 2].  GCs, 
such as cortisol, have been shown to affect a number of biological systems, including 
the immune system.  GCs are postulated to alter thousands of different cellular genes 
[45], including many immune effector genes.  GCs exert effects on immune cells by 
binding to glucocorticoid receptors (GRs), which are present on all immune cells [33, 
34, 46].  GR is a ligand activated transcription factor, which is a member of the 
nuclear receptor super family of proteins.  It predominantly exists within the 
cytoplasm, but when ligand activated, GR translocates to the nucleus [47].  Once in 
the nucleus activated GR can alter gene transcription through recruitment of 
transcription factors, co-regulators and chromatin remodeling proteins [48-51].  These 
interactions between activated GR and other cellular proteins are discussed later (See 
HDACs, HATs and Glucocorticoids).  Under normal conditions GCs are regulated by 
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both the nervous and endocrine systems maintaining homeostasis resulting in proper 
immune cell function.  Individuals experiencing psychological distress exhibit HPA 
activation and elevations in cortisol.  If the stress perception is chronic, disruption of 
the diurnal cortisol rhythm is observed [52, 53], resulting in elevated circulating GCs 
[33, 34, 46].   
A typical diurnal cortisol rhythm is characterized by an initial spike 
approximately 15-45 minutes after waking, this initial spike it termed the cortisol 
awaking rise (CAR) [54].  Cortisol levels then gradually subside throughout the course 
of the day, reaching a minimal level in the evening, just prior to bedtime.  Increases in 
psychosocial distress have been linked to alterations in diurnal cortisol rhythms, which 
can lead to immune cell dysregulation [52, 53].  However, studies have found 
differential interplay between cortisol and psychosocial distress.  Some groups found 
increased CAR with increased activation of the HPA [55, 56] and increased 
psychological stress and depressive mood [57].  Another found relationships between 
increased evening cortisol levels and increased mood disturbance in breast cancer 
survivors [58].   In these studies increased cortisol levels were related to increased 
psychosocial distress.   
However, other studies have measured decreased or blunted cortisol responses 
in relationship to psychosocial distress. Analysis of total cortisol levels measured 
throughout a diurnal rhythm is termed area under the curve.  Women with metastatic 
breast cancer, who report increased perceived stress, have decreased area under the 
7 
 
 
 
curve [52, 59-61] .  Similar findings were found in caregivers, with increased 
depressive mood relating to a decreased cortisol response, throughout the day and 
CAR[62].   
 
Psychosocial Distress and Immune Cell Function: 
A large number of studies have shown that psychosocial distress and GCs 
negatively impact immune function [63-67].  Psychological stress has been shown to; 
alter cytokine production [14, 15, 64, 68, 69], decrease proliferative response to 
mitogens [70-72], reduce specific antibody responses, reduce T-lymphocyte mediated 
cellular responses [73], and decrease synthesis of interferon gamma (IFN gamma) [15, 
74, 75].  In these studies multiple different psychological stressors were related to 
altered immune cell function.  Such stressors included caregiving stress (individuals 
caring for patients with Alzheimer’s disease), post-traumatic stress disorder, exam 
stress and the diagnosis of breast cancer.  Such observations coupled with the well-
established immunosuppressive effect of GC [76], suggest an explanation for the 
reduced immune function associated with increased psychosocial distress.  
However, even though GCs are known to inhibit aspects of immune function 
under some conditions, psychosocial distress and GCs under other conditions can 
promote immune responsiveness [77-81]. Psychological stress has been shown to 
increase circulating levels of tumor necrosis factor alpha (TNF alpha) and interleukin 
one beta (IL-1 beta) levels in humans [82] and in rodents to increase circulating IL-1 
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beta and IL-6 [83, 84]. Moreover, GCs have been shown to synergistically enhance the 
induction of acute-phase proteins by IL-1 beta and IL-6 [85] and the biological effects 
of IL-2, IFN gamma, granulocyte colony-stimulating factor, granulocyte macrophage 
colony-stimulating factor, and oncostatin M [86].  These immune modulating effects 
of GC are concentration and time dependent [87, 88] and it has been clear for many 
years that the effect of the nervous and endocrine system on the immune system are 
not necessarily suppressive.  Substantial evidence demonstrates GC concentrations 
support the activity of the immune system in a permissive and preparative  manner 
[89, 90]. 
 
Natural Killer Cells and Psychosocial Distress: 
NK cells are multi-functional lymphocytes that do not require a pre-activation 
process and are not restricted to antigen presentation by major histocompatibility 
complex molecules [91, 92].  Their rapid action places NK cells as a front line of defense 
against cancer and infectious agents [93-95].  Considerable attention has been paid to the 
direct anti-tumor activities of NK cells [96] and evidence has existed for some time for 
their role in tumor protection.  Moreover, direct evidence has shown these cells to be 
involved in immune surveillance, controlling the initiation and growth of tumors [97-
104].  NK cells produce their effects against tumor cells by first engaging the tumor 
target, followed by exocytosis of NK cytolytic granule constituents against the tumor cell, 
disengagement of the tumor cell by the NK cell and lysis of the tumor targets [91, 92].  
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Reciprocal neuro-chemical pathways and shared receptor systems link the brain 
and the immune system, including NK cells.  In particular, NK cell activity (NKCA) is 
especially responsive to the impact of psychosocial distress and ample evidence 
demonstrates that psychological stress or negative affective states reduce NKCA [15, 63, 
105] and result in a poorer NK cell response to cytokines [71, 106].  Specifically in 
individuals experiencing the diagnosis of breast cancer, increases in perceived stress were 
predictive of decreased NK cell lytic activity [71, 72].  In this same study NK cells were 
also less responsive to known NK stimulators, such as IFN gamma.  An altered cortisol 
rhythm predicted NKCA in women with breast cancer [53], with the levels of distress 
correlating inversely with NKCA [107].  As these women recovered from regional breast 
cancer (8-18 months after diagnosis) distress subsided and NKCA improved [107].  This 
same group also investigated if NKCA dysregulation was related to altered  expression of 
NK cell inhibitory receptors [108].  Although, differential inhibitory molecule expression 
was measured, relationships between the expression of receptors and psychosocial 
distress mediated reductions in NKCA were not found.  Additionally, optimal NK cell 
function is especially important to women with breast cancer, as NK cell function has 
been linked to increased survival in individuals with metastatic disease [109-115].  
Hence, the elevations in psychological distress in response to a diagnosis of breast cancer 
and subsequent reduction in NK cell function may compromise cancer outcomes and/or 
increase risk of cancer reoccurence.  Despite these numerous links between psychosocial 
distress, GCs and NK cell function, molecular mechanisms of NK cell dysregulation in 
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response to psychological distress remain poorly understood.  Understanding molecular 
mechanism(s) contributing to alterations in NK cell function in woman experiencing 
psychosocial distress can lead to the development of approaches to enhance NK response; 
thereby improving disease prognosis.     
 
Epigenetics: Histone Modifications:    
One potential mediator of NK cell dysregulation in response to psychosocial 
distress is epigenetic alterations.  The term epigenetic was first introduced in the 1940s.  
A current working definition  of epigenetic is “molecular or cellular alterations, which 
influence gene expression, and by extension physiology and behavior without causing 
alterations to the DNA sequence itself” [116, 117].   The epigenetic code can now be 
divided into three major parts; DNA methylation, histone modifications and non-coding 
RNAs [117].  All of these epigenetic modifications can regulate gene transcription 
without altering DNA sequence.  The following will focus on a discussion of histone 
modifications.   
Histone proteins H2A, H2B, H3 and H4 dimerize to form an octomeric histone 
core protein [118].  Approximately 147 base pairs of DNA wrap around the histone core 
proteins forming the nucleosome particle.  The histone proteins, possess highly basic 
amino-terminal tail domains located outside of the core nucleosome particle, which are
 
accessible to multiple post-translational covalent modifications [119].  These 
modifications include acetylation, phosphorylation, methylation, sumoylation and 
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ubiquitination [120].  Depending on the modification, these can either lead to activation 
or repression of genes.  Generally, acetylation has been shown to be a mark of activation, 
whereas methylation is a mark of repression [121, 122].  Hyperacetylated genes are 
actively transcribed, whereas hypermethylated genes are repressed.    Reversible 
acetylation of the epsilon amino group of lysine is a dynamic process that regulates 
chromatin structure [123]. Lysine acetylation neutralizes histone proteins, whereas 
deacetylation restores the positive charge of lysines. Following deacetylation, interactions 
between positively
 
charged lysines and the negatively charged DNA phosphodiester
 
backbone, stabilize the DNA/histone complex, restricting nucleosome
 
mobility on the 
DNA, and hindering accessibility of the promoter
 
to transcription machinery [124]. Thus, 
deacetylated lysine residues restrict access of transcription factors for regulatory regions 
of immune effector genes.  By repressing a downstream target of transcription factor 
activation (chromatin accessibility), GCs reduce gene expression irrespective of the exact 
transcription factor requirement for an individual gene.   
Histone acetylation patterns are altered throughout immune cell differentiation 
and this is best characterized in the T lymphocyte populations.  One study found that 
alterations in cytokine profiles of T lymphocytes related to altered histone 3 (H3) and 
histone 4 (H4) acetylation patterns [125].  Specifically differentiation of naïve CD4+ T 
lymphocytes into either Th1 or Th2 lymphocytes resulted in a dynamic interplay between 
acetylation patterns of H3 and H4.  In Th1 lymphocytes increased acetylation of the IFN 
gamma loci occurred, while in Th 2 lymphocytes increased H3 and H4 acetylation of the 
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IL-4 loci occurred.  In CD8+ T lymphocytes connections between H3 acetylation and 
cytotoxicity have been demonstrated.  One study provided evidence that H3-K9-Ac 
contributed to production of cytotoxic molecules such as granzyme B and perforin [126].  
Increases in H3-K9-Ac were related to increased promoter accessibility and increased 
protein production of granzyme B and perforin. 
Associations between NK cells and histone acetylation patterns are less well 
characterized.  There is evidence that H4 acetylation affects cell surface molecules, such 
as inhibitory or activating molecules [127].  This effect is most dramatic with selective 
deacetylation at histone 4 lysine position 8 (H4-K8), resulting in suppressed gene 
transcription [48, 127-129].  Additionally, alterations in H4-K8-Ac have also been linked 
to altered chromatin accessibility [130].  The effects of histone acetylation patterns on 
chromatin structure and on immune response genes are reversible with histone 
deacetylase (HDAC) inhibitors, such as Trichostatin A (TSA) [131-133].  Examination of 
H3 and H4 acetylation patterns in relationship to NK cells cytotoxcity and pro-
inflammatory cytokines remains to be determined.   
 
 
HDACs, HATs and Glucocorticoids:  
Two classes of enzymes are responsible for acetylation patterns of histones; 
HDACs and histone acetylases (HATS).  HDAC activity, either directly or indirectly, 
affects expression of at least 1,120 genes [134].  HDACs are enzymes that remove acetyl 
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groups from the epsilon amino group of lysines on the N-terminal tails of histone proteins 
[135].  HATs transfer acetyl groups onto lysine residues of histone tails [136, 137].  
HDACs are divided into four major classes, Class I – Class IV, based on their homology 
with yeast orthologs. Class I HDACs include HDAC 1, 2, 3, and 8.  While HDAC 1, 2, 
and 3 are ubiquitously expressed, HDAC8’s activity is limited to smooth muscle [138, 
139].  
 
Class II-IV are less well characterized with regard to transcriptional repression and 
in some cases are more restricted in their expression.  Additionally, HDACs 1, 2 and 3 
can be recruited by GR [49-51] leading to transcriptional repression [140].  Work by 
Hong et al. found that cochaperone, Bcl-2 associated athanogene 1 (Bag-1) interaction 
with GR led to transcriptional down regulation by recruitment of nuclear receptor co-
repressor (NcoR) and silencing mediator for retinoic acid and thyroid hormone receptor 
(SMRT), along with HDAC3.  This complex is critical for down regulation of known GC 
response genes.  Work from this laboratory has shown that GC treatment of an NK cell 
line resulted in HDAC1 and SMRT co-localization with GR in NK cells with decreased 
lytic activity [49].  Others found a new Class I specific HDAC inhibitor which measured 
increased NK cell lytic activity of human PBMCs at low nanomolar concentrations, 
suggesting that HDAC1, 2 and 3 are involved in regulation of NK cell lytic activity 
[141].  These data suggest that alterations in Class I HDACs can lead to altered NK cell 
lytic activity.  However, connections between class I HDACs and global histone 
acetylation patterns in NK cells remain to be determined.   
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There are limited connections between HDACs and psychological stress with 
most investigation in experimental animals.  One study in mice did find evidence that 
early life stress alters class I HDACs and histone acetylation [142].  In that study, mice 
which experienced infant maternal separation had decreased expression of class I 
HDACs.  This decrease in expression of class I HDACs related to increased acetylation 
of H4 in the brain of those mice that experienced early life stress when compared to mice 
that did not.  Acetylation status of H4 in the immune cells of these mice was not 
investigated.  Nevertheless this study did suggest that alterations in class I HDACs can 
lead to altered H4 acetylation.  Investigation into GCs, HDACs and psychosocial distress 
in humans remains to be determined.  
Other data suggest that GCs can up-regulate gene expression.  This can occur by 
displacing resident HDACs from gene promoter regions, allowing for histone acetylation 
and transcriptional activation.  One such study showed that 24 hour treatment with Dex 
reduced nuclear expression of HDAC3 [143].  Additionally, interaction of the GR with 
target genes can lead to transcriptional activation via recruit of co-activators and HATs 
[144-146].  HATs are usually divided between type A and type B depending on cellular 
localization [147].  Enzymes such as p300, CPB and pCAF have intrinsic HAT activity.  
Additionally, p300 has been shown to interact with nuclear factors (NF kappa B) [146, 
148], which regulate NK cell lytic activity genes (perforin and granzyme B).  
Additionally, in vitro treatment with a synthetic GC (dexamethasone) increased p300 
HAT activity [143].  These data demonstrate clear evidence of interaction between 
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HDACs and GCs.  However, how these factors interact in NK cells of women 
experiencing psychosocial distress is still unknown.  Further understanding of global 
acetylation patterns and chromatin remodeling protein patterns in women experiencing 
psychosocial distress will allow for a critical assessment of epigenetic mechanisms that 
may mediate immune dysregulation.     
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CHAPTER 3 
SIGNIFICANCE 
Increased psychosocial distress is well documented in women with breast cancer.  
These increases in psychosocial distress lead to HPA activation, which can alter immune 
cell function, with NK cell function found to be especially responsive to these alterations.  
Investigation into potential molecular mechanisms (epigenetic modifications and 
chromatin remodeling proteins) of NK cell dysregulation will provide an important step 
in understanding the effects of psychosocial distress on the immune dysregulation that 
accompanies a diagnosis of breast cancer.  Further understanding of global epigenetic 
modifications and chromatin remodeling proteins could serve as a model for development 
of methods for immune enhancement of individuals during periods of psychological 
stress. 
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CHAPTER 4 
AIMS AND HYPOTHESIS 
Overall Aim:  Determine whether global NK cell epigenetic pattern is associated with the 
immune dysregulation that accompanies the psychosocial distress of breast cancer 
diagnosis.  
 
Specific Aim 1. Characterize an in vitro system to identify effects of GCs treatment on 
global epigenetic pattern and immune cell function. 
Hypothesis 1a.  Dexamethasone treatment of NK92 cells will alter NK cell 
function; lytic activity and cytokine production. 
Hypothesis 1b.  Dexamethasone treatment of NK92 cells will alter global 
epigenetic patterns. 
 
Specific Aim 2.  Characterize the chromatin remodeling proteins associated with global 
epigenetic patterns observed in NK92 cells treated with the glucocorticoid, 
dexamethasone. 
Hypothesis 2a. Global epigenetic patterns of NK92 cells will be associated with 
the cellular localization of chromatin remodeling proteins that repress 
transcription (HDACs). 
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Hypothesis 2b.  Global epigenetic patterns of NK92 cells will be associated with 
the cellular localization of chromatin remodeling proteins that activate 
transcription (HATs). 
 
Specific Aim 3.  Characterize the global epigenetic patterns and the intracellular 
localization of chromatin remodeling proteins of the NK cells of women as they respond 
to and recover from breast cancer diagnosis.  
Hypothesis 3a. Global NK cell epigenetic patterns will differ among women who 
exhibit psychosocial distress mediated immune dysregulation and those who do 
not. 
Hypothesis 3b.  Global epigenetic patterns will relate (correlate) to the immune 
functional activity of the NK cells of women as they respond to and recover from 
breast cancer diagnosis. 
Hypothesis 3c.  The cellular localization of chromatin remodeling proteins will 
differ among the NK cells of women who exhibit psychosocial distress mediated 
immune dysregulation and those who do not. 
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CHAPTER 5 
MATERIALS AND METHODS 
Natural Killer Cell Assay (NKCA):  
 NK cell function was assessed by NKCA. NK cell lytic activity against tumor 
targets was assessed and analyzed using a standard chromium release assay, as previously 
described [15]. K562 tumor cells were radioactively labeled with 100 uCi of [
51
Cr] (New 
England Nuclear, Boston, MA). Radiolabeled K562 cells were incubated for 4 hour with 
peripheral blood mononuclear cells (PBMCs) or 3 hours with NK92 cells. Following 
incubation, the supernatants were removed using a Skatron harvesting press (Skatron 
Inc., Sterling, VA) and the associated radioactivity was determined.   NK92 cell effector 
to target ratios for NKCA was 3, 2, 1 and 0.5:1.  PBMCs effector to target ratios for 
NKCA were 50, 30, 20 and 10:1.   
Results were expressed as % cytotoxicity and calculated by the formula: 
 %  Cytotoxicity =     (experimental DPM*) - (minimum DPM)    x  100.  
            _________________________________ 
    (maximum DPM) - ( minimum DPM)          
All experimental means were calculated from triplicate values.  Lytic units (LU) were 
calculated by a program written by David Coggins, FCRC, Frederick, MD and represents 
the number of cells per 10
7
 effectors required to achieve 20% lysis of the targets. 
*DPM=disintegrations per minute. 
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Cytokine Production (ELISA):  
 NK92 (2.5 x 10
5
 cells/ml) cells were incubated in 24 well plates for 24 hours at 37 
0
C. All molecules were measured using quantitative sandwich enzyme immunoassay 
techniques (Quantikine kits, R & D Systems, Minneapolis, MN). Sensitivities for 
cytokines were; (interleukin-6 (IL-6) <0.7 pg/ml, interferon gamma (IFN gamma) <3 
pg/ml, tumor necrosis factor alpha (TNF alpha) <1.6 pg/ml, and Perforin<40 pg/ml). The 
coefficient of variation ranged between 2.6 – 8.1% for the individually assessed 
molecules. 
PBMCs were unstimulated or stimulated for 48 hours with phorbol 12-myristate 
13-acetate (PMA) and phytoheamagglutin (PHA) (Sigma Aldrich, St. Louis, MO).  PMA 
is a phorbol ester that is a polyclonal activator of PBMCs through activation of protein 
kinase C which leads to protein production.  PHA is able to crosslink proteins expressed 
on the surface of PBMCs causing stimulation.  After 48 hours, supernatants were 
collected and an ELISA was performed.   
 
Intracellular Staining by Flow Cytometry: 
PBMCs: 
PBMCs were aliquoted into fluorescent activated cell sorting (FACS) tubes 
(500,000 cells/tube).  Surface staining antibodies were added for 30 minutes on ice, 
agitated every 15 minutes to identify PBMC sub populations.  Dilutions for all antibodies 
21 
 
 
 
(surface, intracellular and intranuclear) when appropriate was recorded in Supplemental 
Table 3, antibodies not recorded in table were added neat.  Surface antibodies used 
included anti-CD4 (Pacific Blue conjugated), anti-CD8 (PerCP-Cy5.5 conjugated), anti-
CD56 (APC conjugated), anti-CD56 (PE conjugated), anti-CD45RO (APC conjugated), 
anti-CD3 (APC-Cy7 conjugated) and anti-CD14 (APC conjugated) (BD Pharmingen, San 
Jose, CA).  PBMC sub populations were identified as: CD4+ T lymphocytes (CD4+, 
CD8-, CD56-), CD8+ T lymphocytes (CD8+, CD4-, CD56-), Natural Killer (NK) cells 
(CD56+, CD4-, CD8-) and CD14+ Monocytes (CD14+).  Following surface antibody 
staining, the cells were washed twice with 0.1% bovine serum albumin (BSA) (Sigma 
Aldrich, St. Louis, MO) in phosphate buffer solution (PBS) (Gibco, Grand Island, NY).  
PBMCs were fixed and permeabilized with Cytofix/Cytoperm solution (BD Pharmingen, 
San Jose, CA) for 20 min at 4°C. The cells were then washed twice with Perm/Wash 
Buffer (BD Biosciences, San Jose, CA) and probed with antibodies specific for 
intracellular molecules of interest for 1 hour at 4°C.   
For histone residues, anti-acetylated (Ac)-histone 4 lysine 8 (H4-K8) (Millipore, 
Temecula, CA) (unconjugated), anti- H3K9-Ac (Alexa 488 conjugated) (Cell Signalling 
Beverly, MA), anti-trimethylated (me3)-H3K4 (unconjugated ) (Cell Signalling Beverly, 
MA), anti-phosphorylated (P)-H3S10 (Alexa 488 conjugated) (Cell Signalling Beverly, 
MA) were added to cells in FACS tubes. The cells were washed twice with Perm/Wash 
Buffer (BD Biosciences, San Jose, CA), after which secondary anti-immunoglobulin 
gamma (IgG) (FITC conjugated) (Millipore, Temecula, CA) was added for 30 min at 4°C 
22 
 
 
 
to the H4-K8-Ac and H3-K4-me3 tubes.  Following this treatment, the cells were washed 
twice with Perm/Wash Buffer (BD Biosciences, San Jose, CA) and resuspended in 0.1% 
BSA (Sigma Aldrich, St. Louis, MO) in PBS (Gibco, Grand Island, NY).  
For intracellular cytokine analysis, cells were permeabilized and then incubated 
with antibodies specific for intracellular proteins for 1 hour at 4°C.  Antibodies for 
intracellular staining used included anti-IFN gamma (PE conjugated) (BD Biosciences, 
San Jose, CA), anti-granzyme B (Alexa Fluor 647 conjugated) (BD Biosciences, San 
Jose, CA), anti-TNF alpha (PE-conjugated) (BD Biosciences, San Jose, CA), anti-TNF 
alpha (Alexa 488-conjugated) (BD Biosciences, San Jose, CA), anti-IL-6 (PE conjugated) 
(BD Biosciences, San Jose, CA) and anti-perforin (PE conjugated) (BD Biosciences, San 
Jose, CA). For intracellular cytokine analysis of IFN gamma and TNF alpha, cells were 
incubated in leukocyte activation cocktail (LAC) (BD Pharmingen, San Jose, CA) at 
37°C for 4 hours prior to permeabilization and antibody staining.  LAC contains PMA, 
ionomycin and brefeldin A.  PMA is a phorbol ester which is a polyclonal activator of 
PBMCs, ionomycin is a calcium ionphore which increases calcium levels in the cell 
resulting in PBMC stimulation.  Brefeldin A is a protein transport inhibitor which 
allowed for intracellular assessment of cytokines.  For intracellular cytokine analysis of 
IL-6, cells were incubated in leukocyte activation cocktail (BD Pharmingen, San Jose, 
CA) and 100 ng of sonicated lipopolysaccharide (LPS) (Sigma Aldrich, St. Louis, MO) at 
37°C for 4 hours prior to permeabilization and antibody staining.    
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For chromatin remodeling protein analysis, cells were permeabilized and then 
incubated with antibodies specific for chromatin remodeling protein for 1 hour at 4°C.  
For chromatin remodeling proteins, cells were probed with antibodies specific for histone 
deacetylase 1 (HDAC1) (Alexa-647-conjugated)  (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA), HDAC2 (unconjugated) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), 
phosphorylated-HDAC2 (unconjugated) (Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA), HDAC3 (unconjugated) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), p300 
(Alexa 647-conjugated) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).  Secondary 
anti-IgG (FITC conjugated) (Millipore, Temecula, CA) was added for 30 min at 4°C to 
unconjugated primary antibodies.   
For all PBMCs, cytokine and histone mean fluorescent intensities (MFIs) were 
standardized to cytokine and histone MFIs of HiCK Control Cells (BD Pharmingen, San 
Jose, CA). Surface antibodies were not added to HiCK Control Cells; intracellular and 
histone antibodies were added as described above.  HiCK Control Cells were thawed and 
aliquoted into individual microcentrifuge tubes before storage at -80 °C.  On the day of 
PBMC staining, HiCK Control Cells were thawed at 37°C for 2 minutes and then 
aliqoted into FACS tubes for staining.  HiCK Control Cells were stained concurrently 
with PBMCs, therefore staining times, incubations and washes were identical to PBMCs. 
No change in HiCK cell staining was observed over time.  
 
For MFI calculations, the following formula was used: 
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MFI= Cytokine or Histone MFI of sample/Cytokine or Histone MFI of HiCK cell. 
 
After staining, samples were analyzed by flow cytometry with a FACS CantoII 
Fluorescence-Activated Cell Sorter or a LSR Fortessa using FACS Diva software for data 
acquisition [149-151]. 10,000-30,000 events were recorded and analyzed with FlowJo 
v8.4.1. 
 
NK92 cells: 
 NK92 cells were aliquoted into FACS tubes (0.25-1 x 10
5
 cells/tube).  Staining 
protocols, lengths of incubations and antibodies used as previously described for PBMCs.   
Additional antibodies used for NK92 cell staining but not PBMC staining are listed 
below:   
Surface staining antibodies included; anti-CD337 (NKp30) (Alexa Fluor 647 
conjugated) (BD Biosciences, San Jose, CA), anti-CD335 (NKp46) (PE conjugated) (BD 
Biosciences, San Jose, CA) and anti- LFA-1 (CD11a) (FITC conjugated) (BD 
Biosciences, San Jose, CA).  For chromatin remodeling proteins, antibodies used were 
anti-glucocorticoid receptor (GR) (unconjugated) (Abcam, Cambridge, MA), and anti-
mitogen stress kinase-1 (MSK-1)-phosphorylated (unconjugated) (Cell Signaling, 
Boston, MA).  Secondary anti-IgG (FITC conjugated) (Millipore, Temecula, CA) was 
added for 30 min at 4°C to unconjugated primary antibodies.   
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Treatment MFI= (Treatment MFI/Average MFI of No Treatment)x100 
 
After staining, samples were analyzed by flow cytometry with a FACS CantoII 
Fluorescence-Activated Cell Sorter or a LSR Fortessa using FACS Diva software for data 
acquisition [149-151].  For NK92 cells 1,000-10,000 events were recorded and analyzed 
with FlowJo v8.4.1. 
 
Cellular Culture: 
The human erythroleukemic like cell line, K562, was obtained from the American 
Type Culture Collection, Rockville, MD.  K562 cells were maintained in suspension 
cultures in vitro in Corning 75 cm
2
 tissue culture flasks (Corning Glass Works, Corning, 
NY) in RPMI 1640 (Gibco Laboratories, Grand Island, NY) supplemented with 10% fetal 
bovine serum (FBS) low LPS; (Gibco Laboratories, Grand Island, NY), 100 units/ml 
penicillin, 100ug/ml streptomycin (Whittaker M. A. Bioproducts, Walkersville, MD), 0.1 
mM non-essential amino acids, 0.1 mM 2-mercaptoethanol and 2 mM L-glutamine 
(Gibco Laboratories, Grand Island, NY).  K562 cells were passaged every 48 hours with 
media. 
NK92 cells (established from a patient with non-Hodgkin’s lymphoma with the 
capacity to lyse a broad range of leukemia, lymphoma and myeloma cell lines at low 
effector to target ratio in vitro) were obtained from the American Type Culture 
Collection, Rockville, MD and maintained in alpha MEM with 12.5% horse serum 
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(Gibco Laboratories, Grand Island, NY), 12.5% fetal bovine serum (Gibco Laboratories, 
Grand Island, NY), 100 units/ml penicillin, 100ug/ml streptomycin (Whittaker M. A. 
Bioproducts, Walkersville, MD), 0.2 mM inositol (Sigma Aldrich, St. Louis, MO), 0.1 
mM 2-mercaptoethanol (Gibco Laboratories, Grand Island, NY) and 0.02 mM folic acid 
(Sigma Aldrich, St. Louis, MO). NK92 cell cultures were also supplemented with 
interleukin-2 (IL-2) (100 units/ml).  NK92 cells were passaged every 48 hours with 
media and IL-2.  NK92 cell viability is dependent on addition of IL-2. 
 
NK92 Cellular Treatment Systems:  
- Short-Term, High Dose (Dexamethasone 10
-7
M for 24 hours): 
NK92s, cultured at 2.5 x 105 cells/ml, were treated with dexamethasone (Dex) 
(Sigma Aldrich, St. Louis, MO) (10-7 M), for 24 hours in the absence of IL-2.  NK92s 
were washed with media and resuspended to 1 x 10
6
 cells/ml for assay. In a similar 
manner, NK92s were treated with Dex (10
-7
 M) for 24 hours and then Trichostatin A 
(Cell Signaling Technology, Danvers, MA) (100 nM) (TSA) was added to cultures for 1 
to 6 hours.  1 hour TSA treatments were used for NKCA, histone analysis (western and 
flow cytometric) and 6 hour TSA treatments were used for intracellular IFN gamma 
assays. NK92s were washed and resuspended with media to 1 x 10
6
cells/ml.  Cell number 
and viability were determined by exclusion using 0.1% Trypan blue. 
- Chronic Treatment (Dex 10
-10
 M for 5 days): 
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For chronic Dex treatments, NK92s, cultured at 2.5 x 105 cells/ml, were treated with 
Dex (Sigma Aldrich, St. Louis, MO) (10 
-10
M) for 5 days. For the first 4 days of 
treatment, cells were cultured in the presence of IL-2.  For the final 24 hours cells were 
cultured without IL-2.  Cells were counted and resuspended every 48 hours with fresh 
media and Dex. NK92s were washed with media and resuspended to 1 x 10
6
 cells/ml for 
assay. Cell number and viability was determined by exclusion using 0.1% Trypan blue. 
 
Cell Conjugation Assay: 
K562 cells were suspended in 1 ml of 0.1% BSA (Sigma Aldrich, St. Louis, MO) in 
PBS (Gibco, Grand Island, NY) at a final concentration of 5 x 10
6 
cells/ml, then labeled 
for 10 minutes at 37 °C with carboxyfluorescein diacetate, succinimidyl ester (CFSE) (2 
uM, Sigma Aldrich, St. Louis, MO). The cells were washed 3 times with ice-cold 0.1% 
BSA (Sigma Aldrich, St. Louis, MO) in PBS (Gibco, Grand Island, NY). NK92 cells 
were labeled with anti-CD56 (APC-conjugated) (BD Biosciences, San Jose, CA) for 30 
minutes on ice and agitated after 15 minutes. Following antibody staining, the cells were 
washed twice with 0.1% BSA (Sigma Aldrich, St. Louis, MO) in PBS (Gibco, Grand 
Island, NY) and resuspended in alpha-MEM media (Gibco Laboratories, Grand Island, 
NY). NK92 cells at a concentration of 5 x 10
6
/ml were mixed with 5 x 10
6
/ml CFSE-
labeled K562 target cells at an effector to target ratio of 1:1, allowing the formation of 
effector-target conjugates. The NK92-K562 cell mixture was centrifuged at 1,000 
revolutions per minute (rpms) for 2 seconds and incubated at 37 °C for 10 minutes. Then 
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the cell mixture was gently resuspended in 0.1% BSA in PBS and fixed with 1% 
paraformaldehyde (PFA) in PBS (Sigma Aldrich, St. Louis, MO). The conjugation ratio 
was calculated as the portion of CSFE/APC double-positive events [152]. 
 
Western Blot: 
For Western Blot analysis, nuclei of NK92 cells were extracted from 1-5 x 10
6 
cells via the Fermentas ProteoJET Cytoplasmic and Nuclear Protein Extraction protocol 
(Fermentas, Burlington, ON). Nuclei were lysed using Nuclear Lysis Buffer (Fermentas, 
Burlington, ON) and resuspended in Laemmelis SDS-Sample Buffer (4x) (Boston 
Bioproducts, Boston, MA). Samples were boiled for 10 minutes and proteins separated 
by electrophoresis with a 15% agarose gel and transferred to a nitrocellulose membrane 
for blotting. Proteins were visualized with anti- H4-K8 Ac antibodies or anti-H3 
antibodies (Millipore, Temecula, CA), horseradish peroxidase (HRP) conjugated anti-IgG 
secondary antibody (Millipore, Temecula, CA) and chemiluminescence reagent 
(ThermoScientific, Rockford, IL). Blots were standardized to total H3 protein (Cell 
Signaling, Danvers, MA) and blot density quantified using Image J software. 
 
Immunofluorescent Microscopy: 
NK92 cells on glass slides: 
Glass coverslips (Fisher Scientific) were sterilized with 100% ethanol (Sigma 
Aldrich, St. Louis, MO). Coverslips were treated with Cell Tak poly-L-lysine (BD 
29 
 
 
 
Biosciences, Bedford, MA) for 10 minutes to aid adherence of NK92s to coverslips. Dex 
treated and untreated NK92 cells (500,000 cells/coverslip) were added to the coverslips 
for 10 minutes. Coverslips were treated with methanol-free formaldehyde (Polysciences 
Inc., Warrington, PA) diluted in saponin buffer (Sigma Aldrich, St. Louis, MO) for 10 
minutes. This fixed cells to coverslips while maintaining 3D structure of cells. Coverslips 
were washed with PBS. Cells were permeabilized with 0.2% Triton-X (Sigma Aldrich, 
St. Louis, MO) for 12 minutes. Coverslips and cells were blocked for 15-60 minutes with 
0.1% BSA in PBS. Next, antibodies specific for chromatin remodeling proteins were 
added for 1 hour at room temperature. Primary antibodies were added at a 2.5:100 
dilution in 0.1% BSA in PBS. Antibodies used included: anti-HDAC1 (Cell Signaling, 
Danvers, MA) (Abcam, Cambridge, MA), anti-HDAC2 (Cell Signaling, Danvers, MA), 
anti-HDAC3 (Cell Signaling, Danvers, MA) (Abcam, Cambridge, MA) and anti-GR 
(Abcam, Cambridge, MA).  Coverslips were washed with 0.1% BSA in PBS. After 
primary antibodies, secondary antibodies were added for 20-30 minutes at room 
temperature. Secondary antibodies were added at a 1:500 dilution. Secondary antibodies 
to be used were: donkey-anti-mouse IgG (Cy3-conjugated) (Jackson Immunoresearch, 
West Grove, PA) and donkey-anti-rabbit IgG (Alexa 488-conjugated) (Jackson 
Immunoresearch, West Grove, PA). Coverslips were washed with 0.1% BSA in PBS. 
After washing coverslips were fixed to slides with Prolong Gold (Invitrogen, Carlsbad, 
CA) containing DAPI stain for nuclear identification. Images were collected with a 
DeltaVision microscope (Applied Precision) equipped with a digital camera (CoolSNAP 
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HQ; Photometrics), using a 1.4-numerical aperture 100× objective lens, and were 
recorded with SoftWoRx software (Applied Precision). Images were assessed and 
analyzed with Imaris Software. 
 
NK92 Cells- Image Stream: 
 Cellular permeabilization, reagents and antibody staining procedures as described 
above in Intracellular Staining by Flow Cytometry Section.  After staining, samples were 
analyzed by immunofluorescent microscopy with an Amnis Image Stream for data 
acquisition.  For NK92 cells 500-3,000 events were recorded and analyzed with IDEAS 
Software. 
 
Recruitment/Enrollment: 
Women 43-75 years of age, with early stage, breast cancer, treated with breast 
conserving surgery were enrolled.  Some women also underwent radiotherapy and/or 
hormonal therapy. Women were excluded if they were treated with systemic 
chemotherapy, had recurrent breast cancer or other cancers (within the last 5 years), 
immune-based disease (e.g. multiple sclerosis, HIV), psychoses, cognitive dysfunction; 
were not fluent in English, abused controlled substances, were under psychotherapy, took 
anxiolytics, hypnotics, psychotropics, cortico-steroids, or immune-altering drugs.  At 
each time point subjects were screened for infections.  These criteria applied equally to a 
Comparison Group (Control). 
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Missing data were minimal for both psychological and immune data.  Reasons for 
missing immune data were inadequate specimen blood volume, inability to perform 
venipuncture or frank refusal of venipuncture. 
 
Study Outline: 
For all women enrolled psychological instruments were administered, salivary 
cortisol was collected and peripheral blood was obtained.  Women were assessed as they 
responded to and recovered from breast cancer diagnosis at four time points (See Figure 
13).  Data were collected in the period of initial cancer diagnosis (T1), 10-12 days post 
breast surgery and before any adjuvant therapy was initiated (T2).  An interval of 10-12 
days after surgery provided ample time for surgical or anesthesia-induced effects to 
dissipate [110, 153-162]. Hence, this window of time permitted analysis of variables 
without confounds of surgery or adjuvant therapy.  The third time point (T3) was two 
months following radiation treatment completion (for those receiving radiation treatment) 
or approximately four months after diagnosis (for those not receiving radiation treatment) 
and the fourth time point (T4) was six months after radiation treatment completion (for 
those receiving radiation treatment) or approximately 8 months after diagnosis (for those 
not receiving radiation treatment).  PBMCs were isolated from blood specimens obtained 
from these women by a ficol histopaque gradient density separation, as described 
previously [151]. 
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Psychological Assessments: 
 Women completed the Perceived Stress Scale (PSS), which provided a general 
measure of stress (i.e., controllability of life events). Women with breast cancer may 
exhibit depressive symptoms, so the Center for Epidemiologic Studies–Depression (CES-
D) was administered, which captured depressive symptoms, as well as monitored for risk 
of depression. PSS is a 10-item scale that assesses the degree to which a person finds 
their lives as unpredictable, uncontrollable or overloaded (i.e., exceeding their adaptive 
capacities). It is a measure of global stress appraisal, as opposed to a specific event which 
evokes a stress response [163]. Reliability (stability) was 0.85 and Cronbach alphas range 
from 0.75-0.86 [164]. The PSS is widely used in studies of stress on immunity, including 
studies of the stress-immune response of women with breast cancer [15, 107]. PSS was 
shown to be strongly related to trajectories of change in NKCA observed in women as 
they adapted to a diagnosis of breast cancer[107]. CES-D provided a measure of 
depressive symptoms. CES-D assesses frequency and duration of depressive symptoms 
[165]. Scores range from 0-60 and >16 suggests depression risk. CES-D is widely used in 
studies of women with breast cancer [166, 167]. It has good construct validity, good test-
retest reliability [165]. In cancer patients and healthy controls CES-D showed good 
internal consistency (alpha=0.87 and alpha=0.89), respectively [168]. 
 
Selection Criteria- Cancer Pre, Cancer Post, Control: 
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The response to breast cancer diagnosis as assessed by the PSS is quite individual 
and varied for the cohort evaluated, as part of this dissertation.  For example, 28% of the 
Cancer group reported PSS scores that did not change from T1 and T2.  Whereas, PSS 
scores decreased from T1-T2 for 40% of the Cancer group while 32% of the Cancer 
group reported an increase in PSS from T1-T2.  These variations in PSS overtime are 
common in individuals with cancer [39] as individuals vary in their perception of stress, 
coping effectiveness, and supportive networks.  In order to capture results during the 
peak of perceived stress for these women at T1 and T2, a selection technique was used to 
identify a pre radiation time point at which an individual woman expressed the greatest 
level of perceived stress and in addition also demonstrated reduced NKCA. The rationale 
for inclusion of reduced NKCA as additional criteria is that NKCA is highly sensitive to 
the effects of perceived stress [5, 109-114].  For each woman the time point (either T1 or 
T2) where increased PSS and decreased NKCA were measured was selected for the 
Cancer Pre group.  In some Cancer women decreased stress and/or increased NKCA was 
observed at T1 and T2, for these women the time point where the higher PSS and lower 
NKCA was used (see Supplemental Table 7).  This resulted in 27 women selected for 
T1 or T2 time periods out of the total 29 women.  The remaining 2 women were not 
included in this evaluation.  This selection technique was used by other groups as well to 
assess women with increased PSS and decreased NKCA [108, 169].  Limited numbers of 
women enrolled in the Cancer group prevented assessment of a separate group of patients 
exhibiting low PSS and low NKCA. 
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The Cancer Post group assessed Cancer women following radiation treatment.  
For the Cancer Post group either the T3 or T4 time points were chosen that reflected 
decreased PSS.  Limited sample size prevented selection based on NKCA.  This resulted 
in 20 Cancer women selected from T3 and T4 time period out of a total of 22 women.  
The remaining 2 women were not evaluated.  The Cancer women used for the Cancer Pre 
group were the same Cancer women used for the Cancer Post group, simply following 
therapeutic treatment.  For each woman either the T3 or T4 was included.  Additionally, 
availability of psychological and immune data also determined which time point was 
assessed. For the Control group psychological assessments remained consistent 
throughout the study and thus one group was created (Control). 
 
Salivary Cortisol: 
Women collected saliva for measurement of cortisol two days prior to a blood 
draw at each time point. On each of the two collection days, saliva was obtained at 
awakening (“when your eyes open and you are ready to get up”), at 30 minutes after 
wakening, noon, 5 PM and at bedtime (“right before getting into bed”). Women recorded 
collection times on saliva vials. They did not brush their teeth for at least 15 minutes 
prior to collection and abstained from smoking at least 1 hour before sampling. Using 
salivettes (Salimetrics™), subjects gently chewed (60-90 seconds) on a soft swab that fits 
into a holder resting in a centrifuge tube. The morning sample was obtained within 15 
minutes of each person’s wake time [170, 171], while compliance for the later samples 
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was ± 60 min around the sampling time. Women who woke after 11 AM and night shift 
workers were excluded[172]. Centrifuged samples were frozen (-20
0
C) and assayed in 
duplicate within 6 months using immunoassay kits (Salimetrics™). Intra-assay 
coefficient of variation was 3.35-3.65%. Inter-assay coefficient of variation was 3.75-
6.41%. The minimal detectable cortisol concentration  was < 0.003 μg/dL.  The cortisol 
awakening response (the difference between the sample collected at 30 minutes and the 
wakeup sample) was determined. 
 
The waking rise was calculated with the following formula: 
Waking Rise = [(Salivary Cortisol 30 minutes post wakening (ng/ul))-(Salivary 
Cortisol at awakening 9ng/ul))]/[(Time 30 minutes post wakening (minutes))-
(Time Wakening(minutes))] 
 
Statistical Analysis: 
PBMCs: 
 Missing data were treated as such and no imputation techniques were used.  
Independent student t test was performed to analyze differences between the Cancer 
group and Control group at each time point (e.g. Cancer T1 vs. Control T1). A two-sided 
alpha of 0.05 was set for statistical significance. Correlations were examined by 
Pearson’s correlation coefficient with an alpha of p< 0.05 set for statistical significance. 
When data sets were not normally distributed or skewed log transformations were 
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performed on raw data prior to analysis.  Skewness was tested by the Shapiro-Wilks test.  
One-way ANOVAs with Least Significant Difference (LSD) and Bonferroni post hoc 
analysis were used for statistical assessment of selected groups (Cancer Pre, Control and 
Cancer Post). Statistical package for Social Sciences (SPSS: version 15.0) was used for 
data analysis. 
NK92 cells: 
 Data were expressed as means with the standard error of the mean (SEM).  Main 
study variables were analyzed using independent Student’s t test when two groups were 
compared and one-way ANOVA followed by Tukey post hoc analysis when three groups 
were compared.  Pearson’s correlation coefficients were calculated for correlation 
analysis.  A two-sided alpha of 0.05 was set for significance, except as noted.  The 
Statistical Package for Social Sciences (SPSS: version 15.0) was used for data analysis. 
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CHAPTER 6 
RESULTS 
Specific Aim 1. Characterize an in vitro system to identify effects of GCs treatment 
on global epigenetic pattern and immune cell function. 
 
It is well-established that psychosocial distress reduces natural killer cell activity 
(NKCA) [14, 15, 63, 105, 173] and dysregulates cytokine balance mediated by stress-
induced release of glucocorticoids (GCs) [7-9].  This aim sought to identify whether GCs 
(dexamethasone) reduce NK functional activity and alter cytokine production through 
global epigenetic modification of histone residues.  A human NK cell line (NK92 cells) 
was used to identify those functional activities of NK cells that are affected by 
dexamethasone (Dex).  As human samples were limited, an in vitro model system 
provided a screening tool for determining which global epigenetic modifications were 
altered by Dex and also related to NK cell function. 
 
Short-Term, High Dose Dex Treatment (Dex 10
-7 
M for 24 hours) of NK92 cells: 
Effect of Dex on NKCA: 
The ability of Dex to reduce NK92 cell lysis of tumor cell targets was evaluated.  
Treatment of NK92 cells for 24 hours produced a dose-dependent reduction in NK92 
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lytic activity (Figure 1).  A concentration of (10
-7
M) Dex produced an approximate 50% 
reduction in NKCA with no impact on cell viability, as judged by Trypan blue exclusion 
(Supplemental Table 2). 
Effect of Dex on NK92 Adhesion when Engaged by Tumor Cells: 
NKCA requires first the adhesion of NK cells to a tumor cell target, followed by 
the exocytosis of lytic granules, which destroy the tumor cell target.  The ability of NK92 
cells to form conjugates with target cells after Dex treatment was analyzed by flow 
cytometry.  NK92 cells were labeled with APC-conjugated antibodies specific for the NK 
cell surface molecule CD56.  K562 tumor targets were labeled with CFSE.  NK92-K562 
conjugates were measured as double positive (CD56+, CFSE+) populations.  The ability 
of NK92 cells to form conjugates with K562 cells was significantly (p=0.001) decreased 
in response to Dex (10
-7
M), as compared to untreated NK92 cells, Table 1. These results 
indicate that Dex reduced NKCA, in part, by reducing the capacity of NK92 cells to bind 
to K562 target cells.  
Effect of Dex on Production of IFN gamma and Perforin: 
Experiments were conducted to assess the effect of Dex on the capacity of NK92 
cells to produce effector molecules: IFN gamma and perforin.  The effect of Dex on the 
NK92 production of IFN-gamma and perforin production was assessed by ELISA.  A 
dose dependent effect was observed and Dex at 10
-7
M significantly inhibited constitutive 
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IFN-gamma secretion (30.6 ± 1.1 pg/ml vs. 52.5 ± 1.9 pg/ml; p<0.001) and perforin (17.0 
ng/ml vs. 20.5 ng/ml), Figure 2.     
Following cellular activation, Dex also reduced NK92 production of intracellular 
IFN-gamma.  As shown in Figure 3 and Table 2, Dex (10
-7
 M) decreased not only the 
detectable level of the cytokines on a cell-to-cell basis (32.4 ± 2.9% reduction, p<0.0001 
for IFN gamma) but also the percentage of cytokine positive cells (30.9 ± 1.5% 
reduction, p<0.001 for IFN gamma).  In Table 2 the MFI of these detected intracellular 
cytokines are presented and demonstrate a significant reduction in detectable cytokine by 
Dex treatment followed by cellular activation.  
 
Effect of Dex on NK92 Surface and Intracellular Proteins:  
Since Dex treatment of NK92 cells decreased conjugate formation the effect of 
Dex on the capacity of NK92 cells to produce NK adhesion and effector molecules was 
next assessed by flow cytometry.  Adhesion molecules allowed for proper conjugate 
formation resulting in lysis of target cells.  Once inside target cells the effector molecule, 
granzyme B, initiates apoptotic pathways resulting in target cell death.  There was a 
significant reduction in the expression of the lymphocyte adhesion molecule, LFA-1 
(p=0.0001), which is known to mediate binding of NK92 cells to K562 and the granule 
constituent, granzyme B (p=0.022).  In Table 2 MFIs of these surface markers and 
granule constituent are presented.  All NK92 cells stained positive for these molecules, 
therefore no changes in percent positive cells were measured.  Interestingly, these effects 
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were not universal in that the adhesion molecule, CD2 (also know to mediate binding of 
NK92 cells to K562) [174, 175] expression was not decreased. See Table 2. 
 
Effect of Dex on H4-K8 Acetylation: 
To assess the epigenetic effect of Dex, western blot analysis and flow cytometric 
analysis were performed on nuclear extracts derived from NK92 cells, Figure 4, or on 
permeabilized NK92 cells, Table 3.  The blots and permeabilized cells were probed with 
antibodies specific for H4-K8 Ac.  NK92 cells treated with Dex had decreased global 
acetylation of H4-K8 (~50% reduction) when compared to untreated cells as measured by 
western blot.  In Figure 4a, a representative western blot is presented and shows the 
visual reduction in H4-K8 acetylation. Figure 4b illustrates the quantification of western 
blots for the 4 groups of NK92 cells: No Treatment, Dex treated, TSA treated and Dex 
plus TSA. ANOVA demonstrated a significant difference among the 4 groups, 
[F(3,12)=99.526, p<0.0001], such that there was a significant reduction in acetylation of 
H4-K8 with Dex, which was restored by treatment with TSA, a histone deacetylase 
(HDAC) inhibitor.  Dex also reduced acetylation of H4-K8 as judged by flow cytometric 
analysis (~20%) Table 3.  ANOVA demonstrated a significant difference among the 4 
groups, H4-K8 MFI [F(3,11)=33.104, p<0.0001] and H4-K8 % NT [F(3,24)=12.918 
p<0.0001] such that there was a significant reduction in acetylation of H4-K8 with Dex 
which was reversed by treatment with TSA, a HDAC inhibitor.  These effects of Dex 
were not observed with HDAC inhibitor treatment.  Western blot analysis was performed 
41 
 
 
 
on nuclear extracts from NK92 cells and standardized to total nuclear histone 3 (H3) 
proteins.  Flow cytometric analysis evaluated nuclear acetylation of H4-K8 and was 
standardized to cell number, rather than cellular H3 protein.  These differences likely 
account for differential reductions in H4-K8 Ac.   
These global changes in acetylation suggest that the effect of Dex on NK92s was 
a possible consequence of epigenetic modification to promoter regions associated with 
genes essential to NK cell lytic effector function (e.g. perforin and granzyme B).  If this 
was true, then short-term, high dose Dex treatment would reduce accessibility for the 
promoter regions of these genes, perforin and granzyme B.  These epigenetic effects were 
assessed by, chromatin immunoprecipitation (ChIP) with anti-H4-K8 Ac, followed by 
quantitative real time PCR, was used to calculate the fold change in accessibility after 
short-term, high dose Dex treatment.  Short-term, high dose Dex treatment reduced H4-
K8-Ac at both the perforin and granzyme B promoter regions [6]. 
 
Effect of Histone Deacetylase Inhibitor (TSA) on Interferon gamma Production and 
NKCA by Dex Treated NK92 Cells: 
These data suggest that the alteration in NK cell functional activity after short-
term, high dose Dex treatment may result from promoter deacetylation at immune 
relevant genes.  If so, then treatment with TSA would be expected to modify the effects 
of Dex on the functional activity of the NK cells.  NK92 cells were treated with Dex, 
followed by incubation with TSA.  TSA modified the effects of Dex not only for the 
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intracellular production of IFN gamma, Table 4, but also for NK lytic activity against 
tumor targets, Table 5.  ANOVA analysis showed significant differences among the 4 
treatment groups [No Treatment (NT), Dexamethasone (Dex), Trichostatin A (TSA) and 
Dexamethasone plus TSA] for IFN gamma MFI [F(3,15)=46.515, p<0.001] and IFN 
gamma % NT [F(3,15)=49.973, p<0.0001]  Table 4.  Dex significantly reduced detectable 
levels of IFN gamma, but with the addition of TSA, these levels returned to that of the 
untreated cell population.  Likewise for NKCA, Dex significantly reduced lytic activity 
of NK92 cells for tumor targets and treatment with TSA returned NKCA to a level 
produced by untreated NK92 cells, Table 5.  ANOVA analysis showed significant 
differences among the 4 treatment groups [No Treatment (NT), Dexamethasone (Dex), 
Trichostatin A (TSA)  and Dexamethasone plus TSA] NKCA lytic units [F(3,27)=30.770, 
p<0.0001] and NKCA % NT [F(3,36)=44.110, p<0.0001]. 
 
Brief Discussion of Short-Term, High-Dose Dex Treatment of NK92 Cells:   
Short-term, high-dose Dex treatment (10
-7
 M for 24 hrs) reduced NK cell function 
and global H4-K8-Ac in NK92 cells.  Although effects of short-term, high-dose Dex 
treatment were dramatic and impacted both global and gene-specific acetylation changes 
[6] immune functional changes do not completely reflect patterns observed in breast 
cancer patients experiencing psychosocial distress and thus a second in vitro system was 
investigated.  Investigation into dose and duration of Dex exposure on NK92 cells was 
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explored.  Development of a chronic, five day treatment system allowed for increased 
understanding of GCs induced epigenetic and immunologic changes in NK cells.   
Chronic Dex Treatment (Dex 10
-10 
M for 5 days) of NK92 cells: 
 Effect of Chronic Dex Treatment on NKCA: 
The ability of Dex to reduce NK92 cell lysis of tumor cell targets following 
chronic Dex treatment was evaluated.  Chronic Dex treatment of NK92 cells for 5 days 
produced a reduction in NK92 lytic activity, Figure 5.  A concentration of (10
-10
M) Dex 
reduced cytotoxicity at each effector:target ratio (p<0.05) with no impact on cell viability, 
as judged by Trypan blue exclusion (Supplemental Table 2). 
 
Effect of Chronic Dex Treatment on Intracellular IFN gamma: 
Experiments were conducted to assess the effect of Dex on the capacity of NK92 
cells to produce the pro-inflammatory cytokine, IFN gamma.  Following cellular 
activation, chronic Dex treatment increased NK92 production of intracellular IFN-
gamma.  As shown in Figure 6, Dex (10
-10
 M) increased the detectable level of 
intracellular IFN-gamma on a cell-to-cell basis (p<0.05).   
 
Effect of Chronic Dex Treatment on Global H4-K8 Acetylation: 
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To assess the epigenetic effect of chronic Dex treatment, flow cytometric analysis 
was performed on permeabilized NK92 cells.  The permeabilized cells were probed with 
antibodies specific for H4-K8 Ac.  NK92 cells treated with Dex had decreased global 
acetylation of H4-K8 (~20% reduction) when compared to untreated NK92 cells.  In 
Figure 7a, a representative flow cytometric blot is presented and shows the visual 
reduction in global H4-K8 acetylation.  In Figure 7b, the graph shows the quantification 
of 3 independent experiments measuring global H4-K8-Ac by flow cytometry.  Chronic 
Dex treatment of NK92 cells global H4-K8-Ac MFI is standardized to untreated NK92 
cells.   
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Table 1   
Effect of dexamethasone and trichostatin A on conjugate formation of NK92 with target 
cells by flow cytometric analysis. 
 
 
Data are mean values  S.E.M., n>7. Dex= dexamethasone. TSA= Trichostatin A. NT= 
No Treatment. Isotype control MFI was always < 150. % Conjugates = [(No Treatment 
(NT) - Dex or Dex + TSA)/ (No Treatment (NT)] X 100. Statistically significant 
difference, NT vs. Dex, NT vs. Dex + TSA, Dex vs. Dex + TSA. 
  
 
Treatment 
 
 
% Conjugates 
 
P 
value 
(compared 
to NT) 
No Treatment 
(NT) 
 
100 
 
 
   
Dex (10
-7
 M)  73.3  3.3 0.0001 
   
TSA (100 nM) 97.32  6.0 0.975 
   
Dex (10
-7
 M) + TSA (100 nM) 72.23  6.11 0.001 
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Table 2  
Effect of dexamethasone on surface and intracellular proteins of NK92 by flow 
cytometric analysis. 
 
Mean Fluorescent Intensity (MFI) of Surface and Intracellular Proteins 
 
Cellular 
Protein 
 
 
No 
Treatment 
 
Dexamethason
e Treatment 
(10
-
7 M) 
 
P value 
 
% Change 
 
P value 
IFN gamma 
 
376  17 
 
272  4.7 
 
0.004 
 
-31.6  2.8 
 
0.0001 
      
LFA-1 2,722  50 2,377  28 0.0001 -13.1  0.7 0.0001 
      
CD-2 783  12 884  9.0 0.0001 12.8  1.2 0.0001 
      
Granzyme B 63,156   
1178 
57,522  
1706 
0.022 -11.3  2.7 0.001 
 
Values are mean fluorescent intensity (MFI) of surface and intracellular proteins  
S.E.M., N= at least three independent experiments. Isotype control MFI was always < 
150. % Change= (MFI No Treatment - MFI Dexamethasone)/(MFI No Treatment) X 100. 
Statistically significant difference, No Treatment vs. Dexamethasone Treatment. 
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Table 3  
Effect of dexamethasone and trichostatin A on H4-K8 nuclear acetylation of NK92 by 
flow cytometric analysis. 
 
 
Treatment 
 
 
H4K8-Ac 
MFI 
 
P 
value 
(compared 
to NT) 
 
% NT 
(compared 
to NT) 
 
P 
value 
(compared 
to NT) 
 
H4K8-Ac 
MFI 
P 
value 
(compared 
to Dex) 
No Treatment 
(NT) 
 
2,437  18 
 
 
   
0.002 
      
Dex (10
-7
 M) 2,054  71 0.002 79.8  3.9 0.021  
 
      
TSA (100 nM) 2,701  34 0.018 119.7  8.1 0.025  
 
      
Dex (10
-7
 M) + 
TSA (100 nM) 
2,506  47 0.735 106.9  2.8 0.694 0.001 
Data are mean values  S.E.M., n =7. Dex= dexamethasone. TSA= Trichostatin A. NT= 
No Treatment. Isotype control MFI was always < 150. % of  NT = [(No Treatment (NT) - 
Dex or Dex + TSA)/ (No Treatment (NT)] X 100. Statistically significant difference, NT 
vs. Dex, NT vs. Dex + TSA, Dex vs. Dex + TSA. 
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Table 4 
Effect of dexamethasone and trichostatin A on intracellular interferon gamma of NK92 
by flow cytometric analysis. 
 
Treatment 
 
 
IFN 
gamma 
MFI 
 
P 
value 
(compared to 
NT) 
 
% NT 
 
 
P 
value 
(compared 
to NT) 
 
IFN  
gamma 
MFI 
P 
value 
(compared 
to Dex) 
No Treatment 
 
753  22 
 
 
   
0.039 
      
Dex (10
-
7 M)  563  12 0.039 74.8  1.6 0.032  
 
TSA (100 nM) 1255  25 0.0001 166  3.3 0.0001  
 
      
Dex (10
-
7 M) 
+ TSA (100 
nM) 
933  78 0.051 123  10 0.043 0.0001 
 
Data are mean values  S.E.M. N=4. Dex= dexamethasone. TSA= Trichostatin A. NT= 
No Treatment. Isotype control MFI was always < 150.  % of NT and statistically 
significant difference calculated as in Table 4. 
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Table 5   
Effect of dexamethasone and trichostatin A on NKCA of NK92  
 
Treatment 
 
 
Lytic 
Units 
 
P 
value 
(compared to 
NT) 
 
% NT 
 
 
 
 
P 
value 
(compared 
to NT) 
 
Lytic Units 
P 
value 
(compared to 
Dex) 
No Treatment 
 
1202.24  
75 
 
 
   
0.0001 
      
Dex (10
-
7 M)  655.97  
35 
0.0001 51.51  
6.8 
0.0001  
 
      
TSA (100 nM) 1584.32  
95 
0.003 133.5  
11.0 
0.004  
 
      
Dex (10
-
7 M) + 
TSA (100 nM) 
1205.44  
53 
1.0 101.5  
8.2 
0.998 0.0001 
 
Data are mean values  S.E.M. N=7. Dex= dexamethasone. TSA= Trichostatin A. NT= 
No Treatment. % of NT and statistically significant difference calculated as in Table 4. 
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Supplement Table 1.  
Additional Statistical Data for Table 3 
                                   For MFI                                        For % Change 
Cellular 
Protein 
 
t 
 
df 
 
 
t 
 
df 
IFN gamma 
 
5.052 
  
5 
  
11.023 
 
7 
      
TNF alpha 12.505 4  24.832 2 
      
LFA-1 5.941 10  18.307 12 
      
CD-2 -6.541 10  -10.663 5 
      
Granzyme 
B 
2.716 10  4.207 11 
NKp30 
 
18.967 
 
4 
  
72.729 
 
2 
      
NKp46 -14.704 4.511  -16.584 3 
Values are mean fluorescent intensity (MFI) of surface and intracellular proteins  
S.E.M., N= at least three independent experiments. Isotype control MFI was always < 
150. % Change= (MFI No Treatment - MFI Dexamethasone)/(MFI No Treatment) X 100. 
Statistically significant difference, No Treatment vs. Dexamethasone Treatment. 
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Supplemental Table 2   
Percent viability as determined by trypan blue staining  
 
 
Treatment 
 
 
Viability 
No Treatment- 24 hours 
 
No Treatment- 5 Days 
 
86.6  1.1 
 
93.9  0.8 
  
Dex (10
-
7 M)- 24 hours  
 
Dex (10
-10
 M)-5 Days 
87.2  1.3 
 
91.7 1.1 
  
TSA (100 nM) 86.3  1.5 
  
Dex (10
-
7 M) + TSA (100 nM) 84.7  0.8 
  
Data are mean values  S.E.M. N=7. Dex= dexamethasone. TSA= Trichostatin A. NT= 
No Treatment. Viability determined by: [(Number of living NK92 cells)/(total number of 
NK92 cells)]*100   
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Supplemental Table 3.  
 
Flow cytometric and Immunofluorescent Antibody Dilutions 
 
 
Antibodies Specificity-
Conjugate 
 
 
PBMCs 
 
NK92 cells 
 
CD8-PerCP-Cy5.5 
 
1:25 
 
n/a 
   
CD4-Pacific Blue 1:25 n/a 
   
H4-K8-Ac-unconjugated 1:50 1:50 
   
H3K9-Ac-Alexa 488 1:50 1:50 
   
H3K4me3- unconjugated 1:50 1:50 
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Secondary IgG-FITC 
 
Glucocorticoid Receptor- 
unconjugated 
 
MSK-1-phosphorylation-
unconjugated 
 
1:100 
 
n/a 
 
 
n/a 
 
1:100 
 
1:10 
 
 
1:100 
   
Values are dilution factors for antibodies.  n/a= not applicable 
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Specific Aim 2.  Characterize the chromatin remodeling proteins associated with 
global epigenetic patterns observed in NK92 cells treated with the glucocorticoid, 
dexamethasone. 
 
During psychosocial distress immune effector genes are differentially impacted 
with subsets being up-regulated (pro-inflammatory cytokines) [7-9] and others down 
regulated (lytic activity) ) [14, 15, 63, 105, 173].  GCs have been shown to mediate 
immune dysregulation during psychosocial distress by altering global epigenetic patterns 
[5].  However, the mechanism of how GCs impact global epigenetic patterns during 
psychosocial distress remains unknown.  In vitro analysis has shown that GCs can alter 
global epigenetic patterns by interacting with chromatin remodeling proteins [49, 144-
146].  However, chromatin remodeling proteins have not been linked to immune 
dysregulation during psychosocial distress.  Therefore exploratory analysis of chromatin 
remodeling protein cellular localization patterns during chronic GCs treatment would 
advance understanding of molecular mechanisms of immune dysregulation.  
Identification of chromatin remodeling proteins altered during psychosocial distress may 
allow for better understanding of these GCs induced immune effects. 
 
Chromatin Remodeling Protein Levels and Cellular Localization at Day 5: 
 GCs can alter global epigenetic patterns by interacting with chromatin remodeling 
proteins such as HDACs and histone acetylases (HATs).  Previous work has shown that 
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GCs interact with HDAC1, HDAC2, HDAC3 and p300 [49, 143].  Flow cytometry was 
used to determine intracellular total protein levels for Class I HDACs, HAT p300 and 
glucocorticoid receptor (GR) at Day 5.  Figure 8a shows the quantification of three 
independent experiments measuring HDAC1, HDAC2, HDAC3, p300 and GR at Day 5. 
Chronic Dex treated NK92 cells chromatin remodeling protein MFI is standardized to 
untreated NK92 cells chromatin remodeling protein MFI (See Materials and Methods).  
No change in total HDAC1, HDAC2, p300 and GR levels were measured at Day 5.  
Significant reductions in HDAC3 levels were measured. (p<0.05, Figure 8a).  A 
representative FACs plot of total HDAC3 reductions is depicted in Figure 8b.  The black 
line depicts the total HDAC3 levels in untreated NK92 cells, which the dashed grey line 
depicts the reduced total HDAC3 levels in chronic Dex treated NK92 cells. 
Cellular localization of chromatin remodeling proteins of NK92 cells was 
measured by immunofluorescent microscopy on the Amnis Image Stream X (Figure 9).  
Basal cellular localization patterns varied between chromatin remodeling proteins, with 
some proteins measured primarily nuclear (HDAC1, p300) localization, while others 
were distributed into both the cytoplasm and the nucleus (HDAC2, HDAC3 and GR).  
Regardless of cellular treatment, ~75% of NK92 cells followed these staining patterns.  
The remaining ~25% was due to doublet staining or cells improperly imaged.  Figure 9 
depicts a representative image of untreated (Figure 9a) and chronic Dex treated (Figure 
9b) NK92 cells stained for DAPI (nuclear stain),anti-HDAC2 (FITC) and anti-HDAC1 
(APC).  The chronic Dex treated image shows increased nuclear staining of HDAC2 
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(Figure 9).  Quantification of nuclear localization was determined by IDEAS nuclear 
localization wizard software, allowing for measurement of nuclear localization for 1000 
images per treatment.  Increased nuclear localization of HDAC2 was measured at Day 5 
in the chronic Dex treated NK92 cells when compared with the untreated cells (Figure 
10).     
 
Chromatin Remodeling Protein Levels and Cellular Localization at Day 2: 
Slight decreases in intracellular perforin and granzyme B began at Day 2 
(Supplemental Figure 1) therefore chromatin remodeling protein levels were assessed at 
day 2.  Flow cytometry was used to determine intracellular protein levels for Class I 
HDACs, HAT p300 and GR at Day 2.  Figure 11 shows the quantification of 3 
independent experiments measuring HDAC1, HDAC2, HDAC3, p300 and GR at Day 2.  
Chromatin remodeling protein levels (MFIs) of chronic Dex treated NK92 cells are 
standardized to protein levels (MFIs) of untreated NK92 for each experiment (n=3).  No 
change in total HDAC1, HDAC2, HDAC3 p300 and GR levels were measured at Day 2 
(Figure 11).   
 
Phosphorylated Chromatin Remodeling Protein Levels at Day 2: 
 Chromatin remodeling protein cellular localization at Day 2 was assessed by flow 
cytometry.  Phosphorylation of chromatin remodeling proteins can be a marker for 
enzymatic activity and nuclear localization [176].  Flow cytometry was used to determine 
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intracellular phosphorylated protein levels and Figure 12 shows the quantification of 3 
independent experiments measuring phosphorylated HDAC2 and phosphorylated MSK-
1.  Chromatin remodeling protein levels (MFIs) of chronic Dex treated NK92 cells are 
standardized to protein levels (MFIs) of untreated NK92 for each experiment (n=3).   
Significant increases in HDAC2-p were measured at Day 2 in chronic Dex treated NK92 
cells (Figure 12, p<0.05).  No change in MSK-1-p was measured at Day 2 (Figure 12).  
Increases in HDAC2-p at Day 2 suggest that translocation into the nucleus begins as early 
as Day 2, with increased nuclear localization remaining at Day 5 (Figure 10).  
Additionally, increases in HDAC2-p were measured at Day 5, corresponding with 
increased HDAC2 nuclear localization.  
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Specific Aim 3.  Characterize the global epigenetic patterns and the intracellular 
localization of chromatin remodeling proteins of the NK cells of women as they 
respond to and recover from breast cancer diagnosis. 
 
GCs, which are altered during the psychosocial distress of breast cancer diagnosis 
[1-3], are known to impact epigenetic patterns [48, 128, 129].  Changes in epigenetic 
patterns have been linked to changes in gene transcription.  It is possible that the 
mechanism mediating immune dysregulation during psychosocial distress is an 
epigenetic mechanism.  The global epigenetic patterns of women as they respond to and 
recover from breast cancer were analyzed in order to understand whether epigenetic 
mechanisms contribute to psychosocial distress mediated immune dysregulation. 
 
Descriptive Characteristic of Participants: 
 Twenty-nine women were enrolled in the Cancer group and 27 women were 
enrolled in the Control group.  These women were enrolled and evaluated longitudinally 
at 4 times (T1-T4, Figure 13). Demographics, disease and treatment characteristics of 
participants are summarized in Table 6.  Women were predominantly Caucasian in both 
the Cancer (77.4%) and Control groups (70.4%).  The majority of the women were 
married in both the Cancer group (74.2%) and Control group (51.9%).  The majority of 
Cancer women had Stage 0 breast cancer (79.2%) and underwent a combination of 
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surgery, radiation and hormonal treatment (54.2%).  The majority of surgeries were 
breast conserving lumpectomies (70.4%).     
 
Psychological Assessment: 
Psychological assessments administered to the Cancer and Control groups were the 
Perceived Stress Scale (PSS), which measured general appraisal of stress, and the Centers 
for Epidemiologic Studies-Depression (CES-D), which measured depressive mood.  
Women in the Cancer group had increased PSS (Figure 14) and CES-D (Figure 15) 
when compared to the Control group at cancer diagnosis (T1; p<0.01).  Increases in 
perceived stress persisted at T2 (p<0.01), T3 (p<0.05) and T4 (p<0.05) in the Cancer 
group when compared to the Control group (Figure 14). Depressive mood levels of the 
Cancer group returned to levels comparable to Control group at T2, T3 and T4 (Figure 
15). 
 
Natural Killer Cell Activity: 
 Increased PSS have been linked to alterations in NK cell function.  The ability of 
NK cells to lyse tumor cell targets was evaluated for the NK cells of the Cancer and 
Control groups by measurement of NKCA.  NKCA was significantly reduced in the 
Cancer group at T1 when compared with the Control group at T4 (Figure 16, p<0.05).  
Analysis of circulating NK cell percentage showed no difference between Cancer vs. 
Control groups. Data not shown. 
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IFN gamma Production: 
 Increases in PSS have also been associated with alterations in pro-inflammatory 
cytokine production [7-9].  The ability of total peripheral blood mononuclear cells 
(PBMCs) to produce IFN gamma after 48 hour stimulation was measured.  Significant 
increases in produced IFN gamma levels were measured in the Cancer group when 
compared with the Control group (Figure 17) at T3 (p<0.05) and T4 (p<0.05).  IFN 
gamma was not detected in plasma of Cancer or Control groups. 
 
Plasma IL-6: 
 Circulating interleukin-6 (IL-6) levels in the plasma were measured by ELISA.  
Significant increased plasma IL-6 levels were observed in the Cancer group when 
compared with the Control group at T2 (Figure 18, p<0.05).    
 
Psychological, Immunologic and Epigenetic Analysis of Selected Groups of Women: 
 For immunologic and epigenetic analysis a selection technique (described in 
Materials and Methods) was used to assess women at peak stress time periods.  This 
selection technique created three groups, Cancer Pre, Control and Cancer Post.  Cancer 
Pre women reported increased perceived stress and decreased NKCA prior to radiation 
treatment when compared to the Control group.        
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Psychological Assessment of Cancer Pre, Control and Cancer Post Groups: 
Perceived stress and depressive mood were measured in selected groups (Cancer 
Pre, Control and Cancer Post.  The Cancer Pre group had increased PSS (Figure 19a) 
when compared to the Control group (p<0.001) and Cancer Post Group (p<0.05) as 
measured by ANOVA (F2,61=11.7, p=0.0001).  The Cancer Pre group had increased CES-
D (Figure 19b) when compared to the Control group (p<0.001) and Cancer Post Group 
(p<0.05) as measured by ANOVA (F2,62=9.9, p=0.0001). 
  
Natural Killer Cell Activity of Cancer Pre, Control and Cancer Post Groups: 
 As NK cell are especially sensitive to alterations in psychosocial distress the 
ability of NK cells to lyse tumor cell targets was evaluated in the Cancer Pre, Control, 
and Cancer Post groups.  NKCA was significantly reduced in the Cancer Pre group when 
compared with both the Control group (Figure 20; p<0.05) and Cancer Post group 
(Figure 20; p<0.05) as measured by ANOVA (F2,64=3.159, p=0.049).  Analysis of 
circulating NK cell percentages demonstrated no differences among Cancer Pre, Cancer 
Post and Control groups (Figure 21a).   
 
Intracellular IFN gamma of PBMCs of Cancer Pre, Control and Cancer Post Groups: 
 NK cells can lyse tumor cells and produce pro-inflammatory cytokines.  PBMCs 
intracellular IFN gamma levels following 4 hour stimulation with leukocyte activation 
cocktail were measured by flow cytometry.  In the Cancer Pre group, intracellular IFN 
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gamma MFI of NK cells was numerically increased when compared with the Control 
group (Figure 22; p<0.05) and Cancer Post group (Figure 22; p<0.05) and as measured 
by ANOVA (F2,56=8.8, p=0.001).  Increases in intracellular IFN gamma of NK cell 
inversely correlated with NKCA (Table 7).   
Increases in intracellular IFN gamma levels were not limited to the NK cell 
population.  In the Cancer Pre group intracellular IFN gamma MFI of CD4+ T helper 
lymphocytes was numerically increased when compared with the Control group (Figure 
23; p<0.05) and Cancer Post group (Figure 23; p<0.05) as measured by ANOVA 
(F2,54=7.0, p=0.002).  No differences in circulating CD4+ T helper lymphocyte 
percentages were observed among Cancer Pre, Control and Cancer Post (Figure 21b).  
No differences in intracellular IFN gamma levels were measured in CD8+ cytotoxic T 
lymphocytes when comparing the Cancer Pre, Control and Cancer Post groups.  Data not 
shown. 
 
Salivary Cortisol of Cancer Pre, Control and Cancer Post Groups: 
 Hypothalamic-pituitary-adrenocortical (HPA) axis activation produces a cascade 
of neuroendocrine products that result in elevated circulating adrenal derived GCs, which 
is cortisol in humans.  Salivary cortisol was collected 5 times per day for 2 days prior to 
phlebotomy.  Salivary cortisol levels were measured by ELISA and diurnal cortisol 
rhythms were determined.  Cortisol waking rise has been shown to be altered in women 
with breast cancer [59, 60, 177].   No significant differences in cortisol paratmeters were 
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measured between the Cancer Pre and Control groups (Supplemental Table 8).  
Relationships between cortisol waking rise and immunologic function were investigated.  
Significant negative correlations were measured between salivary cortisol and NKCA 
(Table 7, p<0.05) for Cancer Pre and Control groups combined.  Additionally, significant 
positive correlations were measured between cortisol waking rise and intracellular IFN 
gamma of NK (Table 7, p<0.01) and CD4+ T helper lymphocytes (Table 7, p<0.01) for 
Cancer Pre and Control groups combined.  These data suggest that alterations in salivary 
cortisol are associated with immunologic alterations observed in women. 
  
Intracellular Perforin Levels in NK Cells of Cancer Pre, Control and Cancer Post 
Groups: 
 NK cells produce their effects against tumor cells by first engaging the tumor 
target, followed by exocytosis of NK cytolytic granule constituents, such as perforin, 
leading to tumor cell lysis.  Intracellular perforin levels in NK cells and cytotoxic T 
lymphocytes were measured by flow cytometry.  No differences were observed in 
perforin levels in cytotoxic T lymphocytes between Cancer Pre (62.1 10), Control 
(59.38) and Cancer Post (76.215) groups.  Significant positive correlations were found 
between NKCA and perforin levels in NK cells (Table 8; p<0.05).  Relationships 
between CD56 staining intensity and cytotoxic phenotypes of NK cells have been shown 
previously [91, 92].  Therefore staining patterns between CD56 versus perforin were 
analyzed by flow cytometry.  The CD56-dim population stained positively for 
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intracellular perforin (Figure 24).  Representative FACS plots for a Cancer Pre and 
Control woman are shown with the CD56-dim population noted in the box; this 
represents ~90% of the NK cells which is consistent with previous findings [91, 92].  
Additionally, ~90% of the NK cells in the Cancer Pre group also stained positive for 
intracellular IFN gamma (Supplemental Figure 2).  The representative flow histogram 
depicted in Supplemental Figure 2 shows the typical intracellular IFN gamma staining 
pattern for the Cancer Pre group with the majority (89.9%) of the NK cells staining 
positively for intracellular IFN gamma.  These cells had differential CD56 staining, with 
both bright and dim CD56 cells producing IFN gamma.  The same NK cells derived from 
women with breast cancer stained positively for intracellular perforin as were able to 
produce IFN gamma upon stimulation.  These flow cytometric data identify a 
dichotomous phenotype within the NK cells of the Cancer Pre women, with NK cells 
exhibiting both decreased NK cell lytic activity (as measured by NKCA and intracellular 
perforin) and increased intracellular IFN gamma.    
 
Epigenetic Analysis of Cancer Pre, Control and Cancer Post Groups: 
 GCs enter cells by passive diffusion and bind to
 
the intracellular GRs, activating 
GR.  Once activated, GR translocates into the nucleus and can lead to gene repression or 
transcriptional activation by recruiting chromatin remodeling proteins and altering 
epigenetic modifications, such as acetylation.  Increases in acetylation are associated with 
transactivation, while decreased acetylation results in gene repression [6, 121, 122, 129].  
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Global H4-K8-Ac and H3-K9-Ac in NK cells was measured by flow cytometry.  Global 
H4-K8-Ac in NK cells positively correlated with NKCA (p<0.05) and intracellular 
perforin levels (p<0.01) in NK cells (Table 8).  No relationships with global H3-K9-Ac 
and NKCA (Pearson r =0.326, p=0.328) or intracellular perforin (Pearson r=-0.397, 
p=0.227) were found.  These data suggest that global H4-K8-Ac alterations result in 
altered NK cell activity in the Cancer Pre women.  To investigate if decreased global H4-
K8-Ac patterns were measured in women with high perceived stress a median split was 
performed on the Cancer Pre group and the Control groups, creating sub groups with 
individuals with very high perceived stress (PSS mean=251.2)  and very low perceived 
stress (PSS mean=60.7).  Global H4-K8-Ac in NK cells was assessed by flow cytometry 
within these sub groups.  Decreased global H4-K8-Ac in CD56+ NK cells for the Cancer 
Pre, high PSS group was demonstrated when compared to the Control group, low PSS 
(Figure 25; p<0.05).  No significant difference was measured among groups for global 
H3-K9-Ac groups (Figure 27).  CD56 staining patterns did correspond with NK cell lytic 
activity (CD56 dim v. perforin, Figure 24) and intracellular perforin correlated with 
global H4-K8-Ac (Table 8).  Therefore, sub populations of H4-K8-Ac levels relative to 
CD56 were investigated to determine if H4-K8-Ac stained brighter in CD56 dim 
populations.  Staining patterns between CD56 v. H4K8-Ac were investigated by flow 
cytometry.  Representative FACS plots depicted in Figure 26 show uniform staining 
patterns for both Cancer Pre and Control groups with no H4-K8-Ac sub populations 
identified, thus H4-K8-Ac did not stain relative to CD56 staining.   
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To investigate if changes in global histone acetylation patterns were specific to 
NK cell lytic activity relationships between global histone acetylation patterns and CD8+ 
T lymphocytes were also investigated.  CD8+ T lymphocytes have been shown to lyse 
target cells; by first adhering to the cell, followed by granule release of perforin and 
granzymes leading to apoptosis of the target cell.  No relationships were measured 
between global H4-K8-Ac and intracellular perforin in CD8+ T lymphocytes (Pearson 
r=0.252, p=0.121).  Relationships between H3-K9-Ac and intracellular perforin levels 
remain to be determined. 
  
Chromatin Remodeling Proteins Levels of Cancer Pre, Control and Cancer Post Groups: 
 Activation of the HPA axis by psychosocial distress releases GCs.  GCs can alter 
global epigenetic patterns by interacting with chromatin remodeling proteins such as 
HDACs.  Significant inverse correlations were measured between cortisol awakening rise 
and NKCA suggesting that GCs were impacting NK cell lytic function (Table 7).  These 
reductions in NKCA also significantly correlated with decreases in global H4-K8-Ac 
levels in NK cells of the Cancer Pre group.  HDAC levels in NK cells were investigated 
by flow cytometry.  Class I HDAC levels and cellular localization patterns were altered 
in in vitro analysis (Figure 9, 10, 12) therefore HDAC1, HDAC2 and HDAC3 were 
analyzed in the NK cells of the Cancer Pre and Control groups.  Exploratory analysis on a 
subset of Cancer Pre women found increased phosphorylated HDAC2 (HDAC2-p) in the 
NK cells of women with increased PSS (Figure 28).  Phosphorylation of HDAC2 is a 
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marker of nuclear localization and enzymatic activity [176].  No relationships were found 
with HDAC1 or HDAC3.  Due to limited cell numbers, immunofluorescence microscopy 
was not performed. 
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Table 6   
 
Demographics characteristics. 
 Cancer 
(N=29) 
Control 
(N=27) 
 
Age (years) mean  SD 
 
BMI 
 
57.4  9.0 
 
26.2  8.6* 
 
56.2  9.0 
 
21.7  8.0 
 
 
Race 
Caucasian 
African American 
Hispanic 
PI/Asian 
 
Frequency 
 
 
23 
3 
2 
1 
 
 
Frequency 
 
 
19 
3 
1 
4 
 
 
Marital Statusa 
Married 
Divorced/separated 
Single 
 
 
23 
1 
2 
 
 
14
 
6 
4 
99 
 
 
 
Widowed 
 
2 
 
1 
 
 
Incomea 
10,000-29,000 
30,000-59,000 
60,000 and higher 
 
 
1 
7 
17 
 
 
 
 
2
 
3 
21 
 
 
100 
 
 
 
Stage of Cancera 
Stage 0 
Stage I 
Stage IIA 
 
 
 
19 
5 
0 
 
 
 
Treatmenta 
Surgery only 
Surgery + radiation therapy 
Surgery + hormonal therapy 
Surgery + radiation therapy + 
hormonal therapy 
 
Surgery Typea 
Breast conserving 
Mastectomy 
 
 
6 
3 
2 
13 
 
 
19 
8 
 
SD= standard deviation. a=missing data for some women in cohort; answers were 
omitted and no imputation technique was used for missing data. *p=0.05, p value for 
Cancer v. Control. BMI= Body Mass Index 
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Table 7 
 
Correlations for Cancer Pre and Control Groups Combined (a). 
 
 
 
Salivary 
Cortisol 
 
 
NKCA- 
CD56+ 
NK cells 
 
Intracellular 
IFN gamma 
of CD56+ 
NK cells 
 
Intracellular IFN 
gamma of CD4+ 
T lymphocytes 
     
Salivary 
Cortisol 
Waking Rise 
1 -0.311* 
 
0.426** 0.431** 
     
NKCA- 
CD56+ NK 
cells 
-0.311* 
 
1 -0.370* 
 
 
     
Intracellular 
IFN gamma 
of CD56+ 
NK cells 
 
0.426** 
 
-0.370* 
 
 
1 
 
0.849** 
     
Intracellular 
IFN gamma 
of CD4+ T 
lymphocytes 
 
0.431** 
 
 
 
0.849** 
 
1 
Values are Pearson r value, n=44 for Cancer Pre and Control groups combined.  Cancer 
Pre (Cancer women with increased PSS and decreased NKCA prior to radiation 
treatment); Control (decreased PSS and increased NKCA) See Materials and Methods for 
full description.  *p<0.05, ** p<0.01.  Cancer Pre n= 24, Control n= 20. 
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Table 8 
Correlations for Cancer Pre and Control Groups Combined (b). 
 
 
 
 
NKCA 
 
Perforin MFI of 
NK cells 
 
Global H4-
K8-Ac of NK 
cells 
    
NKCA 1 0.358* 
 
0.298* 
 
    
Perforin MFI of NK 
cells 
0.358* 
 
1 0.441** 
    
Global H4-K8-Ac of 
NK cells 
0.298* 0.441** 1 
 
Values are Pearson r value, n=44 for Cancer Pre and Control groups combined.  
Cancer Pre (Cancer women with increased PSS and decreased NKCA prior to 
radiation treatment); Control (decreased PSS and increased NKCA) See Materials 
and Methods for full description.  *p<0.05, ** p<0.01.  Cancer Pre n= 24, Control n= 
20. 
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Supplemental Table 4. 
Surgery Effects on Cancer Women at T2. 
 
 
 
 
Breast 
Conserving 
Lumpectomy 
 
 
Mastectomy 
 
 
p value 
 
 
n 
Breast 
Conserving 
 
n 
Masectomy 
 
PSS 
 
17.3  2.5 
 
20.7  3.5 
 
0.467 
 
15 
 
6 
      
CES-D 
 
 
NKCA 
 
 
IFN 
gamma- NK 
cells 
 
10.8  3.0 
 
 
87.0  18.4 
 
 
0.31  0.04 
12.5  3.3 
 
 
94.4  37.1 
 
 
0.28  0.06 
0.745 
 
 
0.841 
 
 
0.724 
15 
 
 
15 
 
 
15 
6 
 
 
7 
 
 
7 
 
Data are mean values  S.E.M.  p value for Breast Conserving lumpectomy v. 
Mastectomy. 
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Supplemental Table 5. 
Radiation Treatment Effects on Cancer Women at T3. 
 
 
 
 
Radiation 
Treatment 
 
No Radiation 
Treatment 
 
 
p value 
 
 
n 
Radiation 
 
n 
No 
Radiation 
      
PSS 15.7  2.7 14.7  3.0 0.788 9 6 
      
CES-D 
 
 
NKCA 
 
 
IFN gamma- 
NK cells 
12.9  4.8 
 
 
140.7  
32.7 
 
 
0.20  
0.02 
9.7  4.7 
 
 
81.0  38.3 
 
 
0.22  0.03 
0.655 
 
 
0.261 
 
 
0.529 
9 
 
 
9 
 
 
6 
6 
 
 
6 
 
 
7 
      
 
Data are mean values  S.E.M. p value for Radiation Treatment v. No Radiation 
Treatment. 
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Supplemental Table 6. 
IL-6 levels in Cancer Pre and Control groups. 
 
 
 
 
Cancer Pre 
 
Control 
 
 
p value 
 
 
n 
Cancer 
Pre 
 
n 
Control 
      
      
Produced IL-
6 Fold 
Increase 
989.7  
479.2 
172.18  
114.0 
0.115 17 15 
      
Percent IL-
6+ of CD14+ 
monocytes 
11.0  1.3 
 
 
 
6.6  1.4 
 
 
0.039 
 
 
 
17 
 
 
 
16 
 
 
 
 
Data are mean values  S.E.M. p value for Cancer Pre v. Control.  Cancer Pre 
(Cancer women with increased PSS and decreased NKCA prior to radiation 
treatment); Control (decreased PSS and increased NKCA) See Materials and 
Methods for full description. 
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Supplemental Table 7. 
Selection Criteria. 
 
 
 
 
 
PSS-T1 
 
 
NKCA-T1 
 
 
PSS-T2 
 
 
 
NKCA-
T2 
 
Time 
point 
selected 
 
004 
 
13 
 
4 
 
13 
 
7 
 
1 
   
006 
 
009 
 
10 
 
11 
 
12 
 
15 
 
17 
24 
 
27 
 
19 
 
18 
 
20 
 
21 
 
6 
30 
 
79 
 
146 
 
45 
 
133 
 
52 
 
7 
16 
 
34 
 
17 
 
31 
 
20 
 
17 
 
8 
26 
 
59 
 
192 
 
78 
 
75 
 
157 
 
24 
1 
 
2 
 
1 
 
2 
 
2 
 
1 
 
2 
107 
 
 
 
 
18 
 
19 
 
22 
 
23 
 
26 
 
29 
 
 
21 
 
23 
 
n/a 
 
24 
 
7 
 
24 
 
74 
 
110 
 
69 
 
205 
 
41 
 
104 
 
19 
 
13 
 
28 
 
25 
 
6 
 
13 
 
132 
 
44 
 
92 
 
130 
 
33 
 
103 
 
1 
 
1 
 
2 
 
2 
 
2 
 
1 
 
For other data selected missing psychological or immune data determined selection. 
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Supplemental Table 8. 
Other Cortisol Parameters 
 
 
 
 
Cancer Pre 
 
Control 
 
p value 
 
 
Awakening 
 
0.44  0.16 
 
0.420.11 
 
0.942 
   
~30 minutes after 
awakening 
 
Noon 
 
5 pm 
 
Bedtime 
 
Area Under the Curve 
 
0.450.05 
 
0.160.04 
 
0.100.03 
 
0.090.05 
 
1.450.23 
0.360.03 
 
0.09.01 
 
0.070.01 
 
0.060.01 
 
1.330.20 
 
0.237 
 
0.203 
 
0.447 
 
0.622 
 
0.732 
 
Data are mean values  S.E.M. p value for Cancer Pre v. Control.  Cancer Pre 
(Cancer women with increased PSS and decreased NKCA prior to radiation 
treatment); Control (decreased PSS and increased NKCA) See Materials and Methods 
for full description.
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CHAPTER 7 
DISCUSSION 
 The data presented herein identifies global histone 4 lysine 8 acetylation (H4-K8-
Ac) as an epigenetic modification associated with NK cell lytic function.  Additionally, 
HDAC2 was identified as a potential regulator of global H4-K8-Ac in NK cells.  The 
discussion section is divided by treatment systems (short-term, high dose dexamethasone 
(Dex) treatment of NK92 cells, chronic Dex treatment of NK92 cells and ex vivo analysis 
of peripheral blood mononuclear cells (PBMCs) derived from women with breast 
cancer).  In vitro Dex treatment systems results will be discussed independently, before a 
brief comparison of the two systems (Specific Aim 1 and Specific Aim 2).  Ex vivo 
analysis of PBMCs cells derived from women with breast cancer focuses on 
psychological, immune and epigenetic analysis of Cancer Pre, Control and Cancer Post, 
as this selected grouping systems identifies a population of women with increased 
psychosocial distress (Specific Aim 3).  Finally, the discussion section ends with a 
comparison of the in vitro and ex vivo systems. 
Short-Term, High Dose, Dex Treatment of NK92 Cells: 
Therapeutic doses of glucocorticoids (GCs) depress the level of NK cell activity 
(NKCA) in the peripheral blood of treated individuals [178] and physiological 
concentrations of GCs suppress NKCA of PBMCs [4-6]. This inhibition of NKCA is time 
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and dose dependent [4].  In the short-term, high dose, Dex treatment system similar 
concentrations and length of exposure of Dex were used as was assessed in Holbrook et 
al.  It is well-established that acute stress is associated with a reduction in NK cell 
functional activity [64, 179, 180], which may be mediated by increased adrenergic 
activity [181], as well as by the GC hormone, cortisol [182]. This investigation focused 
on the effects of short-term, high dose treatments with the synthetic GC, Dex, on the 
cellular function of the human NK cell line, NK92. The findings demonstrate reductions 
in; NKCA, granule constituents, adhesion to tumor targets and interferon gamma (IFN 
gamma) production. Each of these reductions was associated with reduced global 
acetylation of histone 4 lysine 8 (H4-K8-Ac).  Global reductions in H4-K8-Ac associated 
with Dex treatment suggests that global acetylation patterns may reflects H4-K8-Ac 
patterns at promoter regions of NK cell effector genes (i.e. perforin and granzyme B).  
This was shown to be the case as reductions in global H4-K8-Ac were associated with 
decreased H4-K8-Ac at the proximal promoter regions of perforin and granzyme B 
genes, with concomitant reduction in gene transcription [6].  
 It is well known that GCs can induce gene transcription, yet their major effect on 
the immune system is to suppress transcription. The number of immune response genes 
regulated by GCs is conservatively estimated at more than 1000 [45, 183-185]. GCs can 
decrease cytokine, chemokine, and receptor expression by PBMCs [186]. These effects 
are primarily due to the GC action at the transcriptional level. Although activated 
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glucocorticoid receptors (GR) can directly interact with pro-inflammatory transcription
 
factors like AP-1 (Fos-Jun heterodimers) and NFk-B (p65-p50
 
heterodimers) [187-189], 
the primary effect of GCs are downstream of transcription factor binding to DNA with 
gene repression a consequence of the reversal of histone acetylation [48, 190]. Activated 
GR repress gene
 
expression by direct inhibition of histone acetyl transferase (HAT) 
activity and by active recruitment
 
of histone deacetylase (HDAC) complexes [48].  Most 
importantly, physiologically elevated GC levels induce HDAC expression in a time and 
dose dependent manner [48] resulting in deacetylation of histones, increased tightening of 
DNA, and reduced expression of immune response genes [191]. Moreover, the effect of 
GCs on chromatin structure and on immune response genes is reversible with HDAC 
inhibitors (HDACi) [131-133]. By repressing a downstream target of transcription factor 
activation (chromatin accessibility), GCs reduce gene expression irrespective of the exact 
transcription factor requirement for an individual gene. Hence, the data presented herein 
suggest that one likely explanation for the GC induced reduction in NKCA and in IFN 
gamma production is decreased transcription of immune effector genes due to reduced 
proximal promoter accessibility.  
The results presented herein demonstrate the effect of short-term, high dose Dex 
in this human NK cell line. Further, Dex at the examined concentration and period of 
treatment profoundly reduced the degree of H4-K8 acetylation as judged by western blot 
analysis. Such a global effect of this GC suggests a profound reduction in overall 
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functional NK cell activity. In actuality, reductions in functional activity, although 
significant, approximated 50%. This was true for NKCA, for cytokine production and for 
the accessibility of the promoters IFN gamma, perforin and granzyme B [6]. This 
observation suggests that other effects in addition to transrepression may be ongoing as 
well and may influence the outcome of short-term, high dose Dex treatment and its 
impact on immune function.  Additionally, treatment of NK92 cells with an HDACi 
(TSA) increased both global H4-K8-Ac, NKCA and IFN gamma levels in the presence of 
short-term, high dose Dex concentrations.  These data suggest that global acetylation 
changes mediated by alterations in HDACs are implicated in altered NK cell lytic 
function.  No differences in global H4-K8-Ac MFI were measured when NK92 cells were 
treated with TSA alone when compared to untreated cells (Table 3).  TSA alone did 
significantly increase NKCA and IFN gamma levels when compared to untreated cells 
(Table 4 and 5).  Since TSA inhibits all classes of HDACs it’s possible that treatment of 
NK92 cells with TSA alone causes increases in acetylation of other histone residues 
resulting in increased NKCA and IFN gamma production.  Investigation into other 
histone residue acetylation status is assessed below in ex vivo analysis of NK cells 
derived from women with breast cancer.  TSA inhibits all classes of HDACs, therefore 
although treatment with Dex and TSA suggests that global H4-K8-Ac and NK cell 
functional changes are a result of HDACs it did not answer the question as to which 
HDAC is inhibited.  Currently, there are not any HDAC specific inhibitors available, thus 
no further HDACis were investigated. 
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In contrast to the results described herein, previous work has shown that HDACi 
(valproic acid and suberoylanilide hydroxamic acid) reduce the cytotoxic activity of NK 
cells [192]. NK cell inhibitory effects of HDACi were associated with reduced surface 
expression and function of specific activating receptors (NKp46 and NKp30) responsible 
for the induction of NK cell-mediated cytotoxicity. This inhibitory effect was at the 
transcriptional level as judged by real time PCR. These effects were only seen with IL-2 
activated NK cells, with no effect on fresh NK.  No effect of these HDACi was observed 
for LFA-1 or for IL-2 receptors. Surface expression levels of inhibitory receptors 
including KIR and NKG2A were not influenced by HDACi treatment, indicating a 
specific effect of HDACi on NK cell activating receptors. These differences, with regard 
to the results of this study, may be explained in multiple ways. The likely difference is 
that TSA reversed the effect of dexamethasone within a one to six hour period, while the 
effects of valproic acid and suberoylanilide hydroxamic acid were observed in NK cells 
cultured for 4 days with the HDACi. 
The effect of short-term, high dose Dex treatment on NK92 cells was not limited 
to NKCA and IFN gamma.  Quantitative reductions were also demonstrated for the 
lymphocyte adhesion molecule, LFA-1, which is known to mediate binding of NK92 
cells to K562 [174], as well as the essential granule constituents, perforin and granzyme 
B [175]. These quantitative reductions were not universal in that the adhesion molecule, 
CD2 (also know to mediate binding of NK92 cells to K562) [174, 175] was not affected.  
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In sum, these results associate short-term, high dose Dex treatment induced 
epigenetic histone modification with NK cell function. The acetylation status of H4-K8 
was found to correspond with NKCA, an adhesion molecule known to mediate the 
interaction of NK with tumor cells and granule constituents.  The function of NK cells 
against tumor cells is carried out first by engagement of the tumor target, followed by 
exocytosis of NK cytolytic granule content and/or production of immune effector 
cytokines.  Short-term, high dose Dex treatment of NK92 cells also resulted in decreased 
pro-inflammatory cytokine intracellular and produced levels (IFN gamma).  The 
observation reported herein, demonstrate the effect of short-term, high dose Dex 
treatment to be at the epigenetic level with reduced transcription of immune effector gene 
products required for optimal functional activity of NK cells, leading to a reduction in 
NK cell functional activity.  Further it may be that dose and time of treatment as 
described herein approximate the effect of short term or acute physiological effects of 
this GC and that greater dose and/or more prolonged treatment may reveal a more 
profound outcome and was explored next.  
 
Chronic Dex Treatment of NK92 Cells: 
This investigation focused on the effects of increased time, but decreased 
concentrations of Dex on functional activity of NK92 cells.  Treatment of NK92 cells 
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with high dose Dex (10
-7
) for longer than 24 hours resulted in reduced viability.  Thus, 
decreased concentrations of Dex (10
-10
) were used to assess increased exposure of NK92 
cells to Dex treatment. The findings demonstrate reductions in; NKCA and granule 
constituents (perforin and granzyme B).  Interestingly, these decreases in NK cell lytic 
activity were associated with increased IFN gamma production, resulting in a 
dichotomous NK cell phenotype. Reductions in NKCA, perforin and granzyme B were 
associated with reduced global acetylation of H4-K8-Ac.   
GCs impact global acetylation patterns through recruitment of chromatin 
remodeling proteins.  GCs enter cells by passive diffusion and bind to the ubiquitously 
expressed intracellular GRs.  After a GC binds to GR, ligand activated GR is translocated 
to the nucleus. In the nucleus activated GR regulates the transactivation  or 
transrepression of GC-responsive genes [193].  Ligand activated GR has also been shown 
to impact gene expression through interaction with other chromatin remodeling 
complexes such as HATs and HDACs.  In the data presented herein GR induced 
alterations of class I HDACs (HDAC1, HDAC2, HDAC3) were investigated.  Class I 
HDACs were chosen because previous work has found class I HDACs can interact with 
GR [49-51] and also alterations in class I HDAC function can impact NK cell lytic 
activity [141].  In the chronic Dex treatment of NK92 cells, increased nuclear localization 
of HDAC2 corresponded with decreased global H4-K8-Ac and decreased NKCA 
(Figures 7, 9, 10 and 12 ).  Increased HDAC2 nuclear localization was measured by 
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immunofluorescence and flow cytometric analysis of increased phosphorylation of 
HDAC2 (HDAC2-p), which serves as a nuclear localization signal [176].  Increased 
HDAC2-p was measured at Day 2 (Figure 12), with nuclear localization of HDAC2 
persistent at Day 5 (Figure 10).  These data suggest that HDAC2 nuclear localization 
associated with decreased global acetylation of H4-K8.  Additionally, time course 
analysis suggests that this occurs rapidly, beginning as early as Day 2 of the treatment.  
Analysis of HDAC1 measured no changes in total protein levels, whereas measurement 
of HDAC3 revealed significant decreases to total protein level, suggesting that it is 
HDAC2 responsible for these global decreases in H4-K8-Ac.  Analysis of other classes of 
HDACs will need to be done to confirm that HDAC2 alone is responsible for global 
changes in H4-K8-Ac.  
Cellular localization patterns of GR were investigated in chronic Dex treated 
NK92 cells. Analysis of GR revealed no differences in total protein or cellular 
localization of GR when comparing chronic Dex treated NK92 cells and untreated NK92 
cells [194].  GR cellular localization patterns may not have been observed due to the 
natural cyclic activity of GR, continuous cycling in and out of the nucleus [195-197].  
Studies have shown that GR rapidly translocates in and out of the nucleus during normal 
cellular processes, making measurement of GR co-localization and nuclear localization 
difficult.   
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Alterations in global histone acetylation patterns can be mediated by GCs 
interaction with HATs [136, 137].  As a result cellular levels of p300, a HAT known to 
interact with GR, were investigated in chronic Dex treatment of NK92 cells.  No changes 
in total p300 levels were measured throughout the chronic Dex treatment (Figures 8 and 
11).  Additionally, p300 localized primarily to the nucleus in chronic Dex treatments.  No 
relationships between p300 total levels or cellular localization and global H4-K8-Ac were 
identified.  Analysis of other HATs remains to be determined. 
In sum, these results presented herein found chronic Dex treatment caused a 
dichotomous NK cell phenotype, characterized by decreased NKCA and increased 
intracellular IFN gamma.  Additionally the global acetylation status of H4-K8 was found 
to correspond with decreased NKCA.  The observation reported herein, demonstrate the 
effect of chronic Dex treatment to be at the epigenetic level with reduced transcription of 
NK cell lytic gene products that are required for optimal NCKA.   
 
Comparison of Short-Term, High Dose and Chronic Dex Treatment Systems: 
The effect of psychosocial distress on NK cell function has been, in large part, 
attributed to elevations in GCs produced by stress-induced activation of the 
hypothalamic-pituitary-adrenocortical (HPA) axis [1-3].  GCs have been shown to impact 
gene expression through interactions with chromatin remodeling proteins, such as 
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HDACs and HATs.  Due to limited human sample numbers, in vitro systems to study the 
effects of GCs on NK cell function were established.  The effects Dex on the cellular and 
molecular function of the human NK cell line, NK92 were used.  Two in vitro systems 
were developed; a short term, high dose Dex treatment system and a chronic Dex 
treatment system.  Both systems measured dramatic NK cell functional changes 
following Dex treatment.  Additionally, both short-term, high dose Dex treatment and 
chronic Dex treatment of NK92 cells revealed the novel contribution that GCs can alter 
the epigenome which mediate alterations in NK cell function. 
In both the short term, high dose Dex treatment system and the chronic Dex 
treatment systems significant decreases in NK cell lytic activity as determined by NKCA 
and intracellular levels of granule constituents (perforin and granzyme B) were found.  
This is consistent with previously published results that NKCA is especially responsive to 
alterations in GCs [15, 63, 105].  Additionally, global decreases in H4-K8-Ac were 
associated with decreased NKCA for both treatment systems suggesting that GCs alter 
NKCA through alterations in this epigenetic modification.  Interestingly, with short-term, 
high dose Dex treatment, IFN gamma levels were decreased; whereas with chronic Dex 
treatment, IFN gamma levels were increased.  These opposite results suggest that pro-
inflammatory cytokine regulation by Dex is highly dependent on dose and duration of 
GC exposure.  Interestingly, these varied results could explain discrepancies in the 
literature in regard to psychosocial distress and pro-inflammatory cytokines, where some 
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studies have measured increased pro-inflammatory cytokine levels and others measured 
decreased pro-inflammatory cytokine levels [5, 7-9, 74, 75].  In those studies where 
decreased pro-inflammatory cytokines were found, extreme increases in GCs may have 
resulted in decreased pro-inflammatory phenotype.  In studies where increased pro-
inflammatory cytokines were found (as is in Specific Aim 3), moderate levels of GC 
levels may be the cause.  This theory is further supported by the fact that GCs have been 
shown to be both immunosuppressive and immune-enhancing [9].  Development of these 
two in vitro systems allowed for analysis of global epigenetic modifications associated 
with altered NK cell function.  Additionally, comparison of the two systems allowed for a 
comparison of how dose and duration of GCs can impact NK cells. 
   
Ex Vivo Analysis of Peripheral Blood Mononuclear Cells (PBMCs) Derived from Women 
with Breast Cancer: 
It is well-established that the diagnosis of breast cancer has emotional 
consequences characterized by increased perceived stress, increased depressive mood and 
increased anxiety. Several studies have shown that these emotional consequences [22], 
termed in this dissertation as psychosocial distress, can lead to alterations in immune cell 
function [5, 13-15].  NK cells are highly sensitive to increases in psychosocial distress 
[15, 63, 105], with NKCA inversely correlating with perceived stress [107].  NK cell 
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dysregulation is significant in that NK cells contribute to host protection from cancer 
[102, 103, 198, 199] and NK cell activity has been correlated to increased survival in 
women with metastatic breast cancer [109-114].  Hence, the psychological response to a 
diagnosis of breast cancer diagnosis has clear biological consequence for women with 
breast cancer, as it may negatively impact their prognosis. 
This investigation focused on the effects psychosocial distress on functional 
activity of NK cells with the hypothesis that global epigenetic patterns reflect a molecular 
epigenetic mechanism by which immune function was altered.  This study identified a 
dichotomous phenotype in the NK cells of women with breast cancer, demonstrating 
decreased lytic activity and increased intracellular IFN gamma.  Additionally, global 
acetylation of H4-K8-Ac was identified as an epigenetic modification which correlated 
with NK cell lytic activity and intracellular perforin.  Exploratory analysis identified 
HDAC2 as a potential factor contributing to decreased global H4-K8-Ac and NKCA in 
women experiencing psychosocial distress.  Women with breast cancer (Cancer Pre=prior 
to radiation treatment, See Materials and Methods) had increased PSS and decreased 
NKCA.  These decreases in NKCA positively correlated with both reduced cytoplasmic 
perforin and global nuclear H4-K8-Ac.  Additionally, in women with breast cancer who 
reported extremely high PSS, there was a significant reduction in global H4-K8-Ac when 
compared to Control women who reported low PSS (Figure 25).  It is interesting to note 
that although H4-K8-Ac changes were observed globally, acetylation changes of other 
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histone residues were not observed, specifically no changes were observed at histone 3 
lysine 9 (H3-K9) acetylation (Figure 27).  This is of note as other studies have found 
relationships between H3-K9-Ac and granule components [126].  However in these 
studies, H3-K9-Ac was investigated in promoter regions of granule component genes 
(e.g. perforin and granzyme B), therefore H4-K8-Ac may serve as a better global marker 
of altered NK cell function.  Investigation into H3-K9-Ac in the promoter regions of 
granule component genes has not yet been determined.  These findings suggest that 
global acetylation alterations at H4-K8 were residue specific, suggesting that H4-K8-Ac 
serves as an epigenetic marker for NK cell lytic function.  Analysis of global H4-K8-Ac 
in other immune cell populations did not measure relationships between acetylation status 
and function.  No relationships between global H4-K8-Ac and intracellular perforin and 
granzyme B in CD8+ T lymphocytes were measured.  These data suggest that global H4-
K8-Ac patterns relate to alterations in NK lytic function, but not lytic function of CD8+ T 
lymphocytes.       
The results presented herein demonstrate that the women with breast cancer prior 
to radiation treatment (Cancer Pre) have increased perceived stress as measured by a self-
report questionnaire (perceived stress scale, PSS).  During periods of increased perceived 
stress, activation of the HPA results in elevated circulating adrenal derived GCs, 
primarily cortisol.  Salivary cortisol levels, which correlates with plasma cortisol levels 
[200, 201], was collected to determine diurnal cortisol rhythms in the Cancer Pre, Control 
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and Cancer Post groups.  Cortisol rhythms are characterized by an initial spike 
approximately 30 minutes after waking, this initial spike it termed the cortisol awakening 
rise (CAR).  GC levels then gradually subside throughout the course of the day, reaching 
a minimal level in the evening, just prior to bedtime.  Increases in PSS in the Cancer Pre 
group corresponded with decreased NK cell lytic function as measured by NKCA when 
compared with both the Control and Cancer Post groups.  These decreases in NKCA 
negatively correlate with salivary CAR, thus women with lower NK cell lytic activity 
have higher salivary CAR.  This increase in CAR, may indicate that immune cells were 
exposed to higher levels of cortisol for prolonged periods during the day.  Repeated 
exposure of NK cells to increased CAR may have allowed immune cells to be 
epigenetically primed for immune dysregulation.  Other cortisol parameters still need to 
be assessed.  However, CAR has been shown to be related to increased HPA activation 
[55, 56].  Additionally, HPA activation has been shown to be associated with increased 
psychosocial distress [57], suggesting that CAR was the appropriate cortisol parameter to 
assess.  These correlations between NKCA and CAR suggest that women with increased 
PSS (Cancer Pre) have decreased NKCA as a result of increased NK cell exposure to 
cortisol.  In contrast, NK cells of women with decreased cortisol waking rise (Control) 
may have been exposed to lower cortisol levels resulting in increased NKCA.  Further, 
since NKCA positively correlates with global H4-K8-Ac, cortisol may impact gene 
transcription through recruitment of HDACs, leading to decreased histone acetylation.  
Exploratory analysis of NK cells derived from women with breast cancer investigated 
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relationships between HDAC2-p and global H4-K8-AC.  HDAC2-p is a marker of both 
nuclear localization and enzymatic activity [176].  Breast cancer women with increased 
PSS and decreased global H4-K8-Ac also had increased nuclear HDAC2-p.  These 
finding are the first to identify HDAC2 as a potential mediator of decreased global H4-
K8-Ac and decreased NK cell lytic activity measured during periods of psychosocial 
distress.  Additional analysis to confirm these results is necessary.   
Salivary cortisol levels, however, were not related to PSS scores and there are 
several possible reasons for this.  As enrollment numbers were low, the study at this time 
may be under powered to measure these relationships.  Additionally, in the majority of 
the women, a positive waking rise was measured, however, a small percentage of women 
had a negative waking rise.  This could be due to improper salivary collection or could be 
an individual specific phenotype characterized by a negative waking rise or a blunted 
cortisol response which has been reported previously in women with breast cancer [59, 
60].  At this time not enough women with negative waking rises to evaluate this group 
independently, but would be interesting to investigate this as total sample size increases.  
Finally, several different polymorphisms have been identified in the human GR gene, the 
cognate receptor for GCs.  GR is comprised of three domains; the amino-terminal 
transactivating domain, the DNA binding domain and the carboxy-terminal ligand 
binding domain [202].  The three most characterized polymorphisms are ER22/23K, 
N363S and BcII.  ER22/23K is an amino acid alteration from an arginine to a lysine and 
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N363S is an amino acid switch from an aspragine to a serine, both of these 
polymorphisms are located in the amino-terminal transactivating domain [203, 204].  
BcII identifies a DNA switch from a cytosine to a guanine located in the linker region 
between the transactivating domain and the DNA binding domain.   All three of these GR 
polymorphisms are associated with altered GC sensitivity.  Characterization the GR 
sequence and the number(s) of polymorphisms observed in the women with breast cancer 
may identify a population of women more or less susceptible to fluctuates in cortisol.  
This would allow for further investigations into relationships between PSS and salivary 
cortisol within the population of breast cancer women most susceptible to alterations in 
cortisol rhythm.  
The effect of surgery or radiation treatment on psychological analysis and 
immune function measured herein was investigated.  Studies have shown that an interval 
of 10-12 days after surgery provided ample time for surgical or anesthesia-induced 
effects to dissipate [110, 153-162].  Nevertheless, type of surgery was investigated for 
impact on both psychological states and immune function in the total Cancer group.  The 
majority of the women enrolled in the study were treated with breast conserving 
lumpectomy with a small number of women treated with mastectomy (Table 6 and 
Supplemental Table 4).  No differences in perceived stress and depressive mood were 
measured when comparing the women that underwent breast conserving lumpectomy 
versus women that underwent mastectomy at T2 (Supplemental Table 4).  Differences 
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were investigated at T2 as this was the time point immediately following surgery (Figure 
13).  Additionally, when immune functions were analyzed no differences were measured 
in NKCA and intracellular IFN gamma levels in the NK cells when comparing the 
women that underwent breast conserving lumpectomy versus women that underwent 
mastectomy (Supplemental Table 4).  Radiation treatment effects were also investigated 
in the Cancer group at T3 (Supplemental Table 5).  Psychological and immunological 
analysis did not occur during radiation treatment, however the closest time point, T3, 
occurred 6-8 weeks following the completion of radiation treatment.  The majority of the 
women enrolled in the study were treated with radiation (Table 6), with a small 
percentage undergoing surgery alone or surgery plus hormonal treatment.  No differences 
in perceived stress, depressive mood, NKCA or intracellular IFN gamma levels of the 
NK cells were measured when comparing women that received radiation treatment and 
those that did not (Supplemental Table 5).  These data suggest that neither surgery nor 
radiation treatment impacted psychosocial distress and immune dysregulation.   
Perceived stress was not the only determinant of psychosocial distress associated 
with the diagnosis of breast cancer; increases in depressive mood (CES-D) were also 
measured.  However, analysis of relationships between depressive mood, immune 
function and epigenetic modifications revealed no relationships among these parameters.  
PSS is a measure of global stress appraisal over the previous month, where as CES-D 
assesses depressive mood for the previous week.  Additionally, when analyzing PSS and 
126 
 
 
 
CES-D within all the total groups, PSS was significantly elevated in the Cancer group at 
T1 and T2 (Figure 14), however CES-D was only significantly elevated at T1 (Figure 
15).  Therefore PSS may better capture alterations in psychosocial distress experienced 
by the women with breast cancer over a period of a month.  Additionally, these brief 
alterations in depressive mood may more accurately depict a temporary change in mood 
state not indicative of chronic depression.  Interestingly, previous studies have reported 
dichotomous immune phenotypes in individuals with chronic depression [205].  This 
reported immune phenotype was characterized by decreased NKCA and increased pro-
inflammatory cytokines, specifically IL-6, IL-1 and TNF alpha.  Unlike data presented 
herein, this phenotype in chronic depression was not measured within a single immune 
cell population (e.g. NK cells).  Additionally, in chronic depression this dichotomous 
phenotype was not predicted to be controlled by a single biological hormone (e.g. 
cortisol).  Thus, unlike previous reports the data presented herein suggest the novel 
contribution that cortisol awakening response is associated with a dichotomous 
phenotype in NK cells in women with breast cancer.  Analysis of immune cell function 
and epigenetic modifications within the total Cancer and total Control groups found no 
relationships.  This is likely due to the varied perceived stress trajectories of the Cancer 
group.  Additionally, several of the Control women recruited reported high perceived 
stress making differences between global H4-K8-Ac in the total Cancer versus Control 
groups difficult to discern.  Due to these reasons, immune, cortisol, epigenetic and 
chromatin remodeling protein analysis was performed on the selected groups (described 
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in Materials and Methods section).  Final conclusions await completion of the full study 
as these resulted are highly limited due to inadequate power.  
NK cells derived from women with breast cancer (Cancer Pre group) had 
demonstrably increased intracellular IFN gamma levels when compared to IFN gamma 
levels in NK cells of the Control group (Figure 22).  In women with breast cancer IFN 
gamma levels negatively correlated with NKCA, which strong implies a dichotomous 
phenotype in the NK cells of women experiencing psychosocial distress.  Additionally, 
~90% of the CD56+ cells exhibited both intracellular IFN gamma (Supplemental Figure 
2) and intracellular perforin (Figure 24), further implying that the same population of NK 
cells exhibited reduced tumor cell lysis and increased production of IFN gamma.  
Investigation into relationships between cortisol awaking rise (CAR) and intracellular 
IFN gamma in NK cells did measure significant positive correlations (Table 7).  
Additionally, CAR inversely correlated with NKCA (Table 7).  These data suggest that 
cortisol induced the increases in intracellular IFN gamma and decreases in lytic activity 
in NK cells.  Increases in intracellular IFN gamma levels were not limited to NK cells, 
these increases were also measured in CD4+ T lymphocytes (T helper lymphocytes).  
Additionally, significant positive correlations were measured between CAR and 
intracellular IFN gamma in T helper lymphocytes (Table 7).   
Relationships between intracellular IFN gamma levels and epigenetic 
modifications were investigated; however significant correlations were not measured.  No 
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relationships were measured between global H4-K8-Ac and IFN gamma, further 
suggesting that acetylation at this histone residue is responsible for altered NK cell lytic 
activity.  In NK cells, intracellular IFN gamma levels related to histone 3 serine 10 
phosphorylation (H3-S10-P) (Pearson r =0.248, p=0.15, df=35), whereas in T helper 
lymphocytes IFN gamma levels related to H3-K9-Ac  (Pearson r=0.33, p=0.125, df=23).  
These data suggest that cortisol may produce these effects on IFN gamma through 
alteration in modifications of the tail of H3.  This preliminary analysis corresponds with 
previous work in the field.  Other studies have shown relationships between acetylation 
of H3 relating to IFN gamma in CD4+ T lymphocytes [125].  Those studies measured 
acetylation of H3 at the IFN gamma promoter regions.  Therefore continued analysis of 
IFN gamma in CD4+ T lymphocytes and global H3-K9-Ac could find the novel 
contribution of relating a global modification to pro-inflammatory cytokine production.  
Further analysis to confirm these results is necessary.     
 IFN gamma was not the only pro-inflammatory cytokine measured in the ex vivo 
analysis of NK cells derived from women with breast cancer.  Tumor necrosis factor 
alpha (TNF alpha) and interleukin-6 (IL-6) were also measured.  No differences were 
measured in NK intracellular or produced TNF alpha levels.  Additionally, TNF alpha 
levels were also measured in the plasma and other immune cell populations (CD4+ T 
helper lymphocytes and CD8+ cytotoxic T lymphocytes).  In all cases no differences in 
TNF alpha levels were measured when comparing Cancer Pre, Control and Cancer Post 
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groups.  These data suggest that pro-inflammatory cytokine, TNF alpha is not altered 
during periods of psychosocial distress.   
IL-6 levels were also measured in ex vivo analysis of women with breast cancer.  
Produced IL-6 was measured in both in the plasma and also by ex vivo stimulation of 
peripheral PBMCs in the Cancer Pre and Control groups.  No differences were measured 
in the IL-6 levels in the plasma when comparing the Cancer Pre and Control groups.  A 
trend approaching significance of increased produced IL-6 levels was measured in the 
Cancer Pre group when compared with the Control group (Supplemental Table 6).  For 
this assays total PBMCs were stimulated for 48 hours before supernatants were collected 
and ELISA analysis determined produced IL-6 levels.  Once trends in produced IL-6 
were measured, intracellular flow cytometry was then used to determine which PBMC 
sub population(s) was producing IL-6.  Initial PBMC sub populations investigated were 
NK cells, CD4+ T helper lymphocytes and CD8+ cytotoxic T lymphocytes, however 
minimal intracellular IL-6 levels were detected in these PBMC sub populations.  As a 
result, intracellular IL-6 levels in CD14+ monocytes were also investigated.  A 
significant increase in the percentage of IL-6 producing CD14+ monocytes was measured 
in the Cancer Pre group when compared to the Control group (Supplemental Table 6).  
As intracellular IL-6 staining was not started until differences in produced levels were 
observed, sample size limitations prevent comparison analysis with the Cancer Post 
group.  Analysis of intracellular IL-6 levels remains to be determined.  It is also worth 
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noting that although CD14+ monocyte cells produce IL-6, intracellular flow cytometric 
analysis identified another population of PBMCs which also stained positively for 
intracellular IL-6.  This population has not been identified and remains a future direction; 
however, NK cells, CD4+ T helper lymphocytes and CD8+ cytotoxic T lymphocytes 
have been eliminated as possibilities.  When the CD14+ monocytes were identified as an 
IL-6 producing population of PBMCs, epigenetic analysis on this population also began.  
Global H3-K9-Ac of CD14+ monocytes were measured by intracellular flow cytometry.  
Global H3-K9-Ac patterns were investigated as relationships between H3 modifications 
and IFN gamma were observed.  No differences in global H3-K9-Ac levels in CD14+ 
monocytes were measured when comparing the Cancer Pre with the Control group.  
Relationships were also investigated between percentage of IL-6 producing CD14+ 
monocytes and global H3-K9-Ac of CD14+ monocytes.  Body mass index (BMI) 
independently relates to IL-6 levels [206], therefore BMI was controlled for in correlation 
analysis.  Exploratory analysis between percentage of IL-6 producing CD14+ monocytes 
and global H3-K9-Ac of CD14+ monocytes measured a positive relationship approaching 
significance (Pearson r= 0.789, p=0.062, df=4) between these two variables.  These data 
suggests that global H3-K9-Ac patterns may relate to intracellular IL-6 levels in CD14+ 
monocytes.  Additional analysis on CD14+ monocyte cells will confirm this result.  The 
data presented herein suggests that while H4-K8-Ac is associated with lytic activity, 
modifications of H3 (H3-S10-p and H3-K9-Ac) may be associated with pro-
inflammatory cytokines (IFN gamma and IL-6).   
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Comparison of In Vitro and Ex Vivo Analysis: 
  In vitro analysis provided a screening tool for potential epigenetic modification 
and chromatin remodeling proteins associated with altered GCs.  As human samples were 
limited, this served as a critical tool for determining which modifications and enzymes to 
investigate as well as allowed for assay development.  The chronic Dex treatment system 
best reflected NK cell phenotypes observed in the Cancer Pre group and thus was most 
utilized.  Although the chronic Dex treatment system best represented the human cohorts, 
it was not identical.  For example, chronic Dex treatment reduced granzyme B levels in 
NK92 cells, however no differences were measured in granzyme B levels in the NK cells 
derived from the Cancer Pre group compared to the Control group.  Additionally, NK92 
cells produced IL-6, while NK cell derived from women with breast cancer produced 
minimal IL-6.   
 The two in vitro systems allowed for the dose and time of GC exposure to NK 
cells to be assessed, suggesting the NK cell lytic activity was impacted early in 
treatments and is less dependent on GC levels.  Both short-term, high dose and chronic 
Dex treatment decreased NKCA of NK92 cells.  Interestingly, the impact of GCs on pro-
inflammatory cytokines was dose and time dependent, with short-term, high dose Dex 
treatment decreasing IFN gamma levels and chronic Dex treatment increasing IFN 
gamma levels.  This differential effect would be more difficult to identify in the salivary 
cortisol collections from the selected groups.  Further analysis of the PBMCs derived 
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from women with breast cancer did allow for assessment of multiple immune cell 
populations, which was done in vitro.  Finally comparison of the in vitro and ex vivo 
systems highlights the importance of multiple systems to represent human data, but also 
suggests that while model systems provide an important research tool they cannot 
completely mimic systems in the human body.   
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CHAPTER 8 
 
FUTURE DIRECTIONS 
Identification of HDAC2 as a mediator of decreased global H4-K8-Ac and 
decreased lytic activity in NK cells offers numerous therapeutic possibilities.  Inhibition 
of HDAC2 could be used in treatment of individual experiencing psychosocial distress, 
exhibiting decreased NK cell function and/or women with breast cancer.  The breast 
cancer women enrolled in this study have early stage breast cancer, resulting in minimal 
problems with tumor growth and progression.  Therefore, a therapeutic inhibitor of 
HDAC2 would most likely not be recommended for this population of women.  
However, psychosocial distress and immune dysregulation measured in these women are 
also measured in women with advanced metastatic breast cancer.  It would be interesting 
to investigate HDAC2 inhibitors as a means of increasing NK cell lytic activity to prevent 
tumor cell growth and metastasis in women with advanced breast cancer.  Interestingly, a 
class of drugs termed HDAC inhibitors (HDACi) are already being investigated in a 
number of different disease states, one of which is breast cancer [207, 208].  Nearly all 
HDACis in clinical trials at this time interfere with activity of class I HDACs (HDAC1, 
HDAC2, HDAC3 and HDAC8).  Inhibition of HDACs in tumor cells has been associated 
with decreased tumor cell proliferation and survival.  Therefore, these HDACis offer 
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therapeutic potential for women with metastatic breast cancer to decrease tumor cell 
growth while simultaneously enhancing NK cell lytic activity. 
Investigation into the upstream protein kinase(s) responsible for phosphorylation 
of HDAC2 could also offer potential therapeutic opportunities.  HDAC2 can be 
phosphorylated at four different serine residues; 394, 411, 422 and 424 [209].  
Phosphorylation of serines 394, 422 and 424 is associated with enzymatic activity, with 
the link between phosphorylation of serine 394 (S394) being the strongest [176].  Casein 
kinase 2 alpha 1 (CK2alpha1) has been identified as a protein kinase responsible for 
phosphorylation of HDAC2 at S394 [176, 210].  Unlike other HDACs which can be 
phosphorylated by a number of different kinases, CK2 is unique in its ability to 
phosphorylate HDAC2.  Investigation into CK2 activity could provide a novel pathway 
to directly inhibit only HDAC2.  The data present herein suggests that inhibiting CK2 
and in turn HDAC2-p could also lead to increased NK cell lytic activity.  Links between 
NK cell and CK2 inhibitors are limited with one study measuring increased NK cell lytic 
activity when target tumor cells were pre-treated with CK2 inhibitors [211].  
Interestingly, this study measured increases in NK cell lytic activity to be associated with 
death mediated ligands and not granule components.   One potential future direction 
could be to investigate if inhibition of CK2 impacts NK cell lytic activity, intracellular 
perforin and global acetylation of H4-K8 in the presence of Dex.  Additionally, CK2 
activity has also been found to be elevated in cancer tissues [212].  Inhibition of CK2 
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activity is associated with decreased tumor proliferation and envasion in both esophageal 
and prostate cancer [213, 214].  CK2 promoted tumor cell growth by phosphorylation of 
cellular proteins other than HDAC2.  Relationships between CK2 and HDAC2-p in 
tumor cell progression have not yet been identified.  Although inhibition of CK2s in 
breast cancer has not been investigated these results suggest that interfering with CK2 
could also lead to decreased breast cancer cell growth.  Together these data suggest that 
CK2 inhibitors could also provide a novel cancer therapeutic by decreasing tumor cell 
growth and increasing NK cell activity to individuals with cancer.    
Relationships between PSS and GCs may not have been measured because GCs 
may not have mediated the immunologic effects.  Psychosocial distress upregulates other 
neurotransmitters other than cortisol such as catecholamines.  Stimulation of the 
sympathetic nervous system results in the production of catecholamines such as 
epinephrine and norepinepherine.   Epinephrine and norepinepherine can impact immune 
cells either through direct innervation of lymphoid organs or by secretion into the blood 
stream [215].  Epinephrine and norepinepherine exert their effects through engagement 
with beta-receptors [216].  There are five different beta-receptors that have been 
indentified; beta 1, beta 2, beta 3, alpha 1 and alpha 2.  These beta-receptors are G 
coupled protein receptors that upon activation induce a signaling cascade leading to 
increases in cAMP accumulation, activating protein kinase A within immune cells [217].  
T lymphocytes, NK cells and B lymphocytes have all been shown to express beta 2 
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adrenergic receptor [218, 219].  The impact of these catecholamines on NK cells has not 
been well investigated and results are varied.  Some studies found catecholamines 
decreased NK cell lytic function as measured by NKCA and mRNA levels of granzyme 
B and perforin [217, 220].  Other studies found catecholamines increased NK cell activity 
[221].  Analysis of epinephrine and norepinepherine on NK cell epigenetic modifications 
remains to be investigated.  As neurotransmitters, such as epinephrine and 
norepinepherine, are upregulated during psychosocial distress understanding how 
neurotransmitters impact NK cell function and epigenetic modifications, alone or in 
combination with cortisol is a future direction for this laboratory. 
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CHAPTER 9 
CONCLUSIONS 
    In sum, these results associate GC induced epigenetic histone modifications 
with NK cell function. The acetylation status of H4-K8 was found to correlate with not 
only NKCA but intracellular perforin levels in both ex vivo analysis of NK cells from 
women with breast cancer and Dex treatment of NK92 cells.  Increased nuclear HDAC2 
was associated with decreased global H4-K8-Ac in NK cells, identifying HDAC2 as a 
potential mediator of decreased global H4-K8-Ac.  Additionally, a dichotomous 
phenotype of decreased lytic activity and increased IFN gamma was also identified in NK 
cells from women with breast cancer.  This dichotomous phenotype correlated with 
cortisol awaking rise, suggesting that activation of the HPA and cortisol production 
mediates this effect.  Exploratory analysis found that epigenetic modifications on H3 may 
relate to increased IFN gamma.  Identification of epigenetic modifications associated 
with altered NK cell function highlights the importance of investigation into relationships 
between the epigenome and psychosocial distress. Such analysis has not been previously 
accomplished and this mechanistic insight will advance the science of 
psychoneuroimmunology.  In addition, the findings and technology generated from this 
project can spur future translational studies that can develop epigenetic-based approaches 
as potential indicators of immune cell function.   
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